Diarylamine compound having affinity with Tau protein as well as preparation method and application of diarylamine compound

By developing high affinity and selective diarylamine compounds, the problems of insufficient affinity and off-target binding of existing Tau protein probes in Alzheimer's disease diagnosis have been solved, and efficient Tau protein imaging has been achieved, which has improved the Diagnostic accuracy and treatment monitoring capabilities.

CN119059967AInactive Publication Date: 2024-12-03BEIJING NORMAL UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410701439.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-31
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Tau protein molecular probes have problems such as insufficient affinity, low selectivity and off-target binding in the brain when diagnosing neurodegenerative diseases such as Alzheimer's disease, which affects the accuracy of clinical diagnosis.

Method used

A diarylamine compound with high affinity and selectivity was developed and used for nuclear medicine imaging by suitable radioisotope labeling, especially for diagnosis of neurodegenerative diseases characterized by Tau protein deposition.

Benefits of technology

The compound is able to effectively cross the blood-brain barrier, providing high-resolution Tau protein imaging, improving diagnostic accuracy and therapeutic monitoring capabilities for diseases such as Alzheimer's disease, and reducing nonspecific binding interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119059967A_ABST
    Figure CN119059967A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a diarylamine compound with high affinity with Tau protein as well as a preparation method and application of the diarylamine compound. The diarylamine compound has a structure as shown in a general formula (I). After being labeled by radionuclides, the compound and the derivative thereof can be used for nuclear medicine clinical diagnosis of neurodegenerative diseases, especially for diagnosis of diseases with Tau protein deposition characteristics including Alzheimer's disease. Compound with structure as shown in general formula (I): # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular to a diarylamine compound having affinity for Tau protein and a preparation method and application thereof. Background Art

[0002] As my country's aging population continues to increase, the number of people suffering from Alzheimer's disease (AD) is growing rapidly, and the resulting medical and economic costs are also rising rapidly. According to statistics, as of 2019, there were about 10 million AD patients in my country, making it the country with the largest number of AD patients in the world, accounting for 25% of the total number of AD patients in the world. By 2030, the number of AD patients in my country is expected to exceed 16 million.

[0003] Pathological studies have pointed out that plaques composed of amyloid-β (Aβ) outside nerve cells and neurofibrillary tangles (NFTs) formed by hyperphosphorylated Tau protein inside nerve cells are two important pathological features of AD. Large-scale studies have shown that NFTs in the hippocampus and entorhinal cortex have a significant linear relationship with cognitive decline and cognitive impairment symptoms, because the appearance of NFTs in neurons directly leads to neurological damage. Compared with other medical imaging techniques, Tau-PET imaging is an important means of detecting Tau protein deposition in the brain with high clinical acceptance and good recognition. It can not only provide conclusive information on the changes of Tau protein in the brain over time, but also provide specific information on the location of Tau protein deposition in the brain. Therefore, Tau-PET imaging will play a profound role in the diagnosis of Tau-related diseases, disease staging, and treatment monitoring.

[0004] At present, some molecular probes targeting Tau protein have been developed, such as [ 18 F]T807,[ 18 F]MK6240, 11 C]PBB3 and [ 18 F]THK5351, etc. However, each of them has its own shortcomings. 18 F]T807,[ 18 F]MK6240 and 18 F]THK5351 showed non-target binding in the brain, while [ 11Although PBB3 has high activity and selectivity for Tau protein, it is unstable in the body and will cause nonspecific binding due to metabolism, interfering with clinical diagnosis. Therefore, the development of PET imaging agents with high affinity and selectivity for Tau protein, excellent pharmacokinetic properties and no off-target binding in the brain has important scientific significance and practical value. Summary of the invention

[0005] In view of the problems existing in the existing Tau protein molecular probes, the present invention proposes a diarylamine compound with high affinity for Tau protein and its preparation method and application. The compound has high affinity and selectivity for Tau protein and can be used for nuclear medicine imaging after being labeled with a suitable radioisotope, especially for the diagnosis of patients with neurodegenerative diseases characterized by Tau protein deposition, including Alzheimer's disease.

[0006] In the first aspect, the diarylamine compound provided by the present invention has the following structure of general formula (I):

[0007]

[0008] wherein Ar1 preferably represents

[0009] Among them, I and F can both refer to their isotopes at the same time, such as: 123 / 125 / 127 I and 18 / 19 F;

[0010] Ar2 represents

[0011] R stands for 123 / 125 / 127 I, 18 / 19 F, O 11 / 12 CH3, (OCH2CH2) m R1, Where R1 is 18 / 19 F, m is an integer between 1 and 6.

[0012] Preferably, the diarylamine compound is selected from the following compounds:

[0013]

[0014]

[0015]

[0016] Among them, I and F can both refer to their isotopes at the same time, such as: 123 / 125 / 127 I and 18 / 19 F;

[0017] Among them, in compounds 1-6, compounds 8-37, and compounds 54-58, I is 123 I, 125 I or 127 I;

[0018] In compound 7, compounds 38-53, and compounds 59-60, F is 18 F or 19 F.

[0019] The above preferred compounds have higher activity, higher affinity and selectivity for Tau protein.

[0020] In a second aspect, the present invention also provides derivatives of the above diarylamine compounds, which are pharmaceutically acceptable salts, esters or amide compounds or prodrugs of the diarylamine compounds of the first aspect.

[0021] In a third aspect, the present invention further provides a diagnostic or detection reagent for neurofibrillary tangle disease caused by Tau protein deposition, wherein the active ingredient is the diarylamine compound of the first aspect, and / or its derivatives.

[0022] These diseases include, but are not limited to, Alzheimer's disease, frontotemporal lobar degeneration, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, or Pick's disease.

[0023] In a fourth aspect, the present invention further provides use of the diarylamine compounds and / or their derivatives according to the first aspect in the preparation of nuclear medicine imaging agents.

[0024] Specifically, the nuclear medicine imaging agent is a PET or SPECT imaging agent.

[0025] Compared with the prior art, the present invention has the following advantages:

[0026] The diarylamine compounds provided by the present invention have high affinity and selectivity for Tau protein. After being labeled with a suitable radioactive isotope, they can be used for nuclear medicine imaging, and are particularly suitable for the diagnosis of patients with neurodegenerative diseases characterized by Tau protein deposition, including Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The following is a schematic diagram of the synthesis process of the compounds of Examples 1-12 of the present invention, wherein the reaction reagents and conditions involved are:

[0028] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 6-10 hours; (b) triethylamine, n-hexabutylditin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (d) NaH, anhydrous tetrahydrofuran, 75°C, 3 hours.

[0029] Figure 2 The following is a schematic diagram of the synthesis process of the compounds of Examples 13-15 of the present invention, wherein the reaction reagents and conditions involved are:

[0030] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 8 hours; (b) di-tert-butyl dicarbonate, triethylamine, 4-dimethylaminopyridine, tetrahydrofuran, 90°C, overnight; (c)(1) 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane di(tetrafluoroborate), trimethylsilyl acetate, acetonitrile, room temperature, nitrogen protection, overnight; (2) adamantane spirocyclic ring (SPIAd), saturated sodium carbonate solution, ethanol, room temperature, 30 minutes; (d)(1) 18 F - , K 2.2.2. / K2CO3, DMF, 120°C, 10 min; (2) 1 M HCl, 100°C, 5 min.

[0031] Figure 3 The following is a schematic diagram of the synthesis process of the compounds of Examples 16-31 of the present invention, wherein the reaction reagents and conditions involved are:

[0032] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 6-10 hours; (b) triethylamine, n-hexabutylditin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes.

[0033] Figure 4 The following is a schematic diagram of the synthesis process of the compounds of Examples 32-38 of the present invention, wherein the reaction reagents and conditions involved are:

[0034] (a) 100°C, 3 hours; (b) cuprous acetate, 1,10-phenanthroline, cesium carbonate, DMSO, 90°C, 18 hours; (c) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 90°C, nitrogen protection, 18 hours; (d) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, sodium carbonate, toluene, 100°C, nitrogen protection, 24 hours; (e) 120°C, 3 hours.

[0035] Figure 5 The following is a schematic diagram of the synthesis process of the compounds of Examples 39-45 of the present invention, wherein the reaction reagents and conditions involved are:

[0036] (a) triethylamine, hexabutyltin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 12-24 hours;

[0037] (b)Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (c) I2, acetonitrile, reflux, 4 hours.

[0038] Figure 6 The following is a schematic diagram of the synthesis process of the compounds of Examples 46-57 of the present invention, wherein the reaction reagents and conditions involved are:

[0039] (a) Potassium tert-butoxide, DMSO, 100°C, overnight; (b) Triethylamine, hexabutyl ditin, tetratriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (d) NaH, DMF, 160°C, 2 hours; (e) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 6-10 hours; (f) NaH, anhydrous tetrahydrofuran, 75°C, 3 hours.

[0040] Figure 7 The following is a schematic diagram of the synthesis process of the compounds of Examples 58-70 of the present invention, wherein the reaction reagents and conditions involved are:

[0041] (a) NaH, anhydrous tetrahydrofuran, 75°C, 6-8 hours; (b) triethylamine, hexabutyl ditin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (d) di-tert-butyl dicarbonate, triethylamine, dioxane, reflux, overnight; (e) (1) Na 125I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (2) 100°C, 5 minutes; (f) potassium bis(trimethylsilyl)amide (1M THF solution), 100°C, 3-6 hours; (g) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, potassium tert-butoxide, dioxane, 110°C, nitrogen protection, 12 hours.

[0042] Figure 8 Schematic diagram of the synthesis process of compounds of Examples 71-79 of the present invention, wherein the reaction reagents and conditions involved are:

[0043] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 4-10 hours; (b) triethylamine, hexabutyl ditin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes.

[0044] Fig. 9 Schematic diagram of the synthesis process of compounds of Examples 80-89 of the present invention, wherein the reaction reagents and conditions involved are:

[0045] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, potassium tert-butoxide, dioxane, 110°C, nitrogen protection, 4-10 hours; (b) NaH, anhydrous tetrahydrofuran, 75°C, 6-10 hours.

[0046] Fig.10 The following is a schematic diagram of the synthesis process of the compounds of Examples 90-96 of the present invention, wherein the reaction reagents and conditions involved are:

[0047] (a) tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 4-10 hours; (b) trimethylamine, trifluoroacetic anhydride, dichloromethane, room temperature, half an hour; (c) 18 F -, tetrabutylammonium bicarbonate, DMSO, 100°C, 6 minutes; (d) di-tert-butyl dicarbonate, triethylamine, dichloromethane, reflux, overnight; (e)(1) 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane di(tetrafluoroborate), trimethylsilyl acetate, acetonitrile, room temperature, nitrogen protection, overnight; (2) adamantane spiro ring (SPIAd), saturated sodium carbonate solution, ethanol, room temperature, 30 minutes; (f)(1) 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane di(tetrafluoroborate), trimethylsilyl acetate, acetonitrile, room temperature, nitrogen protection, overnight; (2) 6.10-dioxaspiro[4.5]decan-7,9-dione, saturated sodium carbonate solution, ethanol, room temperature, 30 minutes; (g)(1) 18 F - , K 2.2.2. / K2CO3, DMF, 120-140°C, 10 minutes; (2) 1M HCl, 100°C, 5 minutes.

[0048] Fig.11 The following is a schematic diagram of the synthesis process of the compounds of Examples 97-108 of the present invention, wherein the reaction reagents and conditions involved are:

[0049] (a) Potassium bis(trimethylsilyl)amide (1M THF solution), 100°C, 3-6 hours; (b) Tris(dibenzylideneacetone)dipalladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, cesium carbonate, dioxane, 110°C, nitrogen protection, 6-10 hours; (c) Triethylamine, n-hexabutyltin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (d) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (e) NaH, anhydrous tetrahydrofuran, 75°C, 6-8 hours.

[0050] Fig.12 The following is a schematic diagram of the synthesis process of the compounds of Examples 109-115 of the present invention, wherein the reaction reagents and conditions involved are:

[0051] (a) NaH, anhydrous tetrahydrofuran, 75°C, 7 hours; (b) triethylamine, hexabutyl ditin, tetrakistriphenylphosphine palladium, dioxane, 110°C, nitrogen protection, 10 hours; (c) Na 125 I, 3% hydrogen peroxide, 1M hydrochloric acid, room temperature, 15 minutes; (d) I2, dichloromethane, room temperature, 2 hours.

[0052] Fig.13 The probe in Example 117 of the present invention [ 125 I]1-3, [ 125 I]7,[ 125 I]9-10,[125 I]16-18, 125 I]22-26, 125 I]32-34, [ 125 I]36,[ 125 I]38,[ 125 I]45,[ 125 I]46,[ 125 I]48,[ 125 I]50-52, 125 I]56,[ 125 I]58,[ 125 I]59,[ 125 I]63,[ 125 I]64,[ 125 I]69,[ 125 I]71-74, 125 I]103,[ 125 I]105-106, 125 I]109 and [ 125 I]116 Autoradiographic results of brain tissue sections of AD patients (female, 95 years old, frontal lobe; female, 102 years old, temporal lobe; female, 95 years old, temporal lobe; male, 95 years old, temporal lobe; female, 97 years old, frontal lobe).

[0053] Fig.14 The probe in Example 117 of the present invention [ 18 F]13 Autoradiographic results of brain tissue sections of AD patients (A, female, 95 years old, frontal lobe), (B, female, 102 years old, temporal lobe), (C, male, 78 years old, temporal lobe), (D, female, 70 years old, temporal lobe), (E, female, 74 years old, temporal lobe), (F, female, 91 years old, temporal lobe), (G, female, 87 years old, temporal lobe).

[0054] Fig.15 For the probe in Example 117 of the present invention [ 18 F]88 Autoradiography results in brain tissue sections of AD patients (A, female, 87 years old, temporal lobe), (B, female, 102 years old, temporal lobe), (C, male, 79 years old, temporal lobe), (D, male, 95 years old, temporal lobe), (E, female, 91 years old, temporal lobe), (F, female, 95 years old, temporal lobe).

[0055] Fig.16 is compound 10 ( Fig.16 A), compound 13 ( Fig.16 B), compound 59 ( Fig.16 C), compound 63 ( Fig.16 D), compound 64 ( Fig.16 E), compound 88 ( Fig.16F), compound 98 ( Fig.16 G) and compound 101 ( Fig.16 H) Tau IC 50 value.

[0056] Fig.17 For the compound in Example 120 of the present invention [ 18 F]13( Fig.17 A) and compound [ 18 F]88( Fig.17 B) TauK d Determination of values ​​(male, 78 years old, temporal lobe).

[0057] Fig.18 In Example 122 of the present invention, 18 F]13 PET / CT imaging results in ICR mice (male, 18-20g), where Fig.18 A is [ 18 Time activity curve of F]13 in PET imaging of ICR mouse brain, Fig.18 B is the brain of ICR mice [ 18 F]13PET imaging, Fig.18 C is the whole-body MIP image of ICR mouse PET imaging.

[0058] Fig.19 In Example 122 of the present invention, 18 F]13 PET / CT imaging results in SD rats (male), Fig.19 A is [ 18 The time activity curve of F]13 in PET imaging of SD rat brain, Fig.19 B is the PET image of the brain and the whole body MIP image of SD rats.

[0059] Fig. 20 In Example 122 of the present invention, 18 F]13 PET / CT imaging results in rhesus monkeys (female, 38 years old), Fig. 20 A is [ 18 Time activity curve of F13 in PET imaging of rhesus monkey brain, Fig. 20 B is the brain of rhesus monkey [ 18 F]13PET imaging and whole-body MIP images.

[0060] Fig.21 In Example 122 of the present invention, 18 F]88 PET / CT imaging results in SD rats (male), the left picture is the PET imaging of the brain and the whole body MIP image of SD rats, the right picture is [ 18 Time activity curve of F]88 in PET imaging of SD rat brain. DETAILED DESCRIPTION

[0061] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0062] Example 1: Synthesis of Compound 1

[0063]

[0064] 7-Aminoquinoline (144.3 mg, 1 mmol) and 1,4-diiodobenzene (336.1 mg, 1 mmol), cesium carbonate (917.8 mg, 3 mmol), tris(dibenzylideneacetone)dipalladium (92.1 mg, 0.1 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (93.6 mg, 0.2 mmol) were dissolved in 10 mL of dioxane, protected by nitrogen, and reacted at 110°C overnight. After the reaction was completed, the solvent was removed under reduced pressure and separated by column chromatography to obtain 116.3 mg of yellow powder with a yield of 33.6%. 1 H NMR (400MHz, CDCl3) δ8.76(d,J=4.3Hz,1H),8.08(d,J=8.1Hz,1H),7.70(d,J=3.3Hz,2H),7.58(d,J=7 .1Hz,2H),7.36–7.31(m,1H),7.28(s,1H),7.00(d,J=7.2Hz,2H),6.31(s,1H).HRMS:m / z=347.00378[C 15 H 12 N2I] + .

[0065] Example 2: Synthesis of Compound 2

[0066]

[0067] According to the synthesis method of Example 1, compound 28 was synthesized using 6-aminoisoquinoline and 1,4-diiodobenzene as raw materials to obtain 101.1 mg of yellow powder with a yield of 29.1%. 1 H NMR (400MHz, CDCl3) δ9.04(s,1H),8.36(d,J=5.8Hz,1H),7.84(dd,J=9.0,3.2Hz,1H),7.65(d,J=8.5H z,2H),7.42(d,J=6.0Hz,2H),7.24(s,1H),7.02(d,J=8.5Hz,2H),6.23(s,1H).HRMS:m / z=347.00385[C 15 H 12 N2I] + .

[0068] Example 3: Synthesis of Compound 3

[0069]

[0070] According to the synthesis method of Example 1, compound 29 was synthesized using 6-aminoquinoline and 1,4-diiodobenzene as raw materials to obtain 153.2 mg of yellow powder with a yield of 44.2%. 1 H NMR (400MHz, CDCl3) δ8.73(d,J=4.1Hz,1H),8.07(dd,J=12.8,9.2Hz,1H),8.00(t,J=8.2Hz,1H),7.61(d,J=6.9H z,2H),7.45(dq,J=6.0,3.3,2.8Hz,1H),7.36(s,2H),6.98(d,J=6.8Hz,2H),6.07(s,1H).HRMS:m / z=347.00391[C 15 H 12 N2I] + .

[0071] Example 4: Synthesis of Labelled Precursor 4

[0072]

[0073] Dissolve the intermediate compound 1 (34.8 mg, 0.1 mmol), tetrakistriphenylphosphine palladium (23.1 mg, 0.02 mmol) and n-hexabutyl ditin (230.4 mg, 0.4 mmol) in 10 mL of dioxane, add 1 mL of triethylamine, protect with nitrogen, react overnight at 110°C, after the reaction is completed, remove the dioxane by vacuum distillation, add dichloromethane, filter, remove the dichloromethane by vacuum distillation, and separate by column chromatography (petroleum ether: ethyl acetate = 3:1). 9.3 mg of colorless oily product is obtained, with a yield of 18.2%. 1 H NMR (400MHz, CDCl3) δ8.77(d,J=2.7Hz,1H),8.01(d,J=8.1Hz,1H),7.68(d,J=8.8Hz,2H),7.42(d,J=8.0Hz,2H),7.25–7.21(m,3H),7.19( dd,J=8.2,4.4Hz,1H),6.05(s,1H),1.63–1.52(m,6H),1.40–1.33(m,7H),1.09–1.03(m,3H),0.95–0.87(m,11H).HRMS:m / z=511.21341[C 27 H 39 N2Sn] + .

[0074] Example 5: Synthesis of Labeled Precursor 5

[0075]

[0076] According to the synthesis method of Example 4, compound 2 was used as a raw material to synthesize the labeled precursor 5 to obtain 12.3 mg of a pale white oily product with a yield of 17.7%. 1 H NMR (400MHz, CDCl3) δ9.01(s,1H),8.31(d,J=5.9Hz,1H),7.81(s,1H),7.45(d,J=8.2Hz,2H),7.41(d,J=5.9Hz,1H),7.27(dd,J=5.8,1.9Hz, 2H),7.22(d,J=8.2Hz,2H),6.20(s,1H),1.63–1.51(m,6H),1.40–1.29(m,8H),1.10–1.02(m,4H),0.93–0.85(m,9H).HRMS: m / z=511.21326[C 27 H 39 N2Sn] + .

[0077] Example 6: Synthesis of Labeled Precursor 6

[0078]

[0079] According to the synthesis method of Example 4, compound 3 was used as a raw material to synthesize the labeled precursor 6 to obtain 21.4 mg of a colorless oily product with a yield of 35.2%. 1 H NMR (400MHz, CDCl3) δ8.68(dd,J=4.5,1.4Hz,1H),8.23(s,1H),8.11(d,J=6.0Hz,1H),7.51(d,J=10.3Hz,1H),7.45(d,J=8.2Hz,2H),7.39(d,J=2. 5Hz,2H),7.21(d,J=8.2Hz,2H),6.11(s,1H),1.65–1.55(m,6H),1.40–1. 30(m,8H),1.10–1.03(m,4H),0.95–0.87(m,9H).HRMS:m / z=511.21313[C 27 H 39 N2Sn] + .

[0080] Example 7: Synthesis of Compound 7

[0081]

[0082] 2-Aminoquinoxaline (145.5 mg, 1 mmol) and sodium hydride (206.1 mg, 5 mmol) were added to 10 mL of anhydrous tetrahydrofuran, stirred for 30 minutes under ice bath, 1,4-diiodobenzene (332.9 mg, 1 mmol) was added, and the mixture was reacted at 65°C for 3 hours. 10 mL of water was added to quench the reaction, and the mixture was extracted with dichloromethane three times. The solvent was removed under reduced pressure, and the mixture was separated by column chromatography (ethyl acetate: petroleum ether = 1:3) to obtain 55.2 mg of a light yellow powder with a yield of 44.2%. 1 H NMR (400MHz, CDCl3) δ8.40(s,1H),7.92(dd,J=8.2,1.2Hz,1H),7.80(dd,J=8.3,1.3Hz,1H),7.67(d,J=8.9Hz,2H),7.6 3(dd,J=8.3,1.4Hz,1H),7.57(d,J=8.9Hz,2H),7.49(ddd,J=8.3,7.0,1.4Hz,1H),6.86(s,1H).HRMS:m / z=347.99902[C 14 H 11 N3I] + .

[0083] Example 8: Synthesis of Labeled Precursor 8

[0084]

[0085] According to the synthesis method of Example 4, compound 7 was used as a raw material to synthesize the labeled precursor 8 to obtain 12.9 mg of a bright yellow oily product with a yield of 22.0%. 1 H NMR (400MHz, CDCl3) δ8.46(s,1H),7.92(dd,J=8.2,1.3Hz,1H),7.79(dd,J=8.5,1.1Hz,1H),7.68(d,J=8.3Hz,2H),7.65–7.60( m,1H),7.49–7.44(m,2H),1.59–1.50(m,6H),1.39–1.28(m,6H),1.09–1.03(m,4H),0.93–0.85(m,11H).HRMS: m / z=512.20837[C 26 H 38 N3Sn] + .

[0086] Example 9: Synthesis of Compound 9

[0087]

[0088] According to the synthesis method of Example 1, compound 9 was synthesized using 6-aminoquinoxaline and 1,4-diiodobenzene as raw materials to obtain 127.3 mg of yellow powder with a yield of 63.0%. 1 H NMR (600MHz, CDCl3) δ8.70(s,1H),8.63(s,1H),7.97(d,J=9.0Hz,1H),7.64(dd,J=8.7,2.0Hz,2 H),7.59(s,1H),7.43(d,J=9.1Hz,1H),7.06–7.01(m,2H),6.21(s,1H).HRMS:m / z=347.99896[C 14 H 11 N3I] + .

[0089] Example 10: Synthesis of Compound 10

[0090]

[0091] According to the synthesis method of Example 1, compound 10 was synthesized using 1,5-naphthyridin-2-amine and 1,4-diiodobenzene as raw materials to obtain 277.3 mg of yellow powder with a yield of 57.1%. 1 H NMR(400MHz, (CD3)2SO) δ9.76(s,1H),8.65(dd,J=4.2,1.5Hz,1H),8.12(d,J=9.2Hz,1H),8.06(d,J=7.8Hz,1H),7.8 6(d,J=8.9Hz,2H),7.65(d,J=8.8Hz,2H),7.59(dd,J=8.4,4.2Hz,1H),7.29(d,J=9.2Hz,1H).HRMS:m / z=347.99911[C 14 H 11 N3I] + .

[0092] Example 11: Synthesis of Labeled Precursor 11

[0093]

[0094] According to the synthesis method of Example 4, compound 9 was used as a raw material to synthesize the labeled precursor 11 to obtain 35.7 mg of a yellow oily product with a yield of 37.3%. 1H NMR (400MHz, CDCl3) δ8.68(s,1H),8.59(s,1H),7.94(d,J=9.0Hz,1H),7.59(s,1H),7.45(d,J=8.0Hz,3H),7.42–7.35(m,1H),7 .24(s,1H),6.14(s,1H),1.62–1.49(m,6H),1.40–1.28(m,6H),1.12–0.96(m,4H),0.93–0.86(m,11H).HRMS:m / z=512.20831[C 26 H 38 N3Sn] + .

[0095] Example 12: Synthesis of Labeled Precursor 12

[0096]

[0097] According to the synthesis method of Example 4, compound 10 was used as a raw material to synthesize the labeled precursor 12 to obtain 19.4 mg of a colorless oily product with a yield of 14.5%. 1 H NMR (400MHz, CDCl3) δ8.68(dd,J=4.3,1.5Hz,1H),8.12(d,J=9.2Hz,1H),8.06(d,J=9.2Hz,1H),7.56(d,J=8.3Hz,2H),7.50(d,J=4.3Hz,1H),7. 47(d,J=8.3Hz,2H),7.19(d,J=9.2Hz,1H),1.64–1.48(m,4H),1.39–1.2 9(m,7H),1.10–1.00(m,6H),0.95–0.84(m,10H).HRMS:m / z=512.20868[C 26 H 38 N3Sn] + .

[0098] The schematic diagram of the synthesis process of the compounds of Examples 1-12 above is shown in Figure 1 .

[0099] Example 13: Synthesis of Compound 13

[0100]

[0101] According to the synthesis method of Example 1, compound 13 was synthesized using 1,5-naphthyridine-2-amine and p-fluorobromobenzene as raw materials to obtain 88.2 mg of white powder with a yield of 73.6%. 1H NMR (400MHz, CDCl3) δ8.69(dd,J=4.3,1.5Hz,1H),8.13(d,J=9.1Hz,1H),8.05(ddd,J=8.5,1.5,0.8Hz,1H ),7.60(dd,J=9.1,4.8Hz,2H),7.50(dd,J=8.5,4.3Hz,1H),7.09(t,J=8.8Hz,3H).HRMS:m / z=240.09314[C 14 H 11 N3F] + .

[0102] Example 14: Synthesis of Compound 14

[0103]

[0104] Compound 10 (262.2 mg, 0.75 mmol), di-tert-butyl dicarbonate (1.6 g, 7.5 mmol), and 4-dimethylaminopyridine (91.5 mg, 0.75 mmol) were dissolved in 10 mL of tetrahydrofuran, and triethylamine (76.1 mg, 0.75 mmol) was added. The mixture was reacted at 90° C. overnight, and the solvent was removed under reduced pressure. The mixture was separated by column chromatography (ethyl acetate: petroleum ether=4:1) to obtain 301.7 mg of a white solid with a yield of 89.9%. 1 H NMR (600MHz, CDCl3) δ8.88(s,1H),8.38(d,J=8.9Hz,1H),8.12(d,J=8.4Hz,1H),7.94(d,J=8.9 Hz,1H),7.69(d,J=7.4Hz,2H),7.55(dd,J=8.0,3.8Hz,1H),7.00(d,J=7.4Hz,2H),1.47(s,9H).

[0105] Example 15: Synthesis of Compound 15

[0106]

[0107] Compound 14 (88.8 mg, 0.2 mmol), 1-chloromethyl-4-fluoro-1,4-diazotized bicyclo[2.2.2]octane di(tetrafluoroborate) (178.4 mg, 0.5 mmol), trimethylsilyl acetate (80.0 mg, 0.6 mmol) were dissolved in 8 mL of acetonitrile, nitrogen was protected, and the reaction was carried out at room temperature overnight. After the reaction was completed, the solvent was removed under reduced pressure, 30 mL of water was added, and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 10 mL of 0.5 M sodium acetate / acetic acid mixed solution, and the organic phase was removed under reduced pressure. N-pentane / dichloromethane (v / v=10 / 1) was added and ultrasonicated to obtain a solid, and the residual solvent was removed in vacuo. The solid obtained in the first step was dissolved in 10 mL of ethanol, and the adamantane spiro ring (SPIAd) was added to a saturated sodium carbonate solution, and the ethanol solution was added dropwise together, and the pH value of the solution was adjusted to be greater than 10. After 30 minutes at room temperature, 30 mL of water was added, and the solution was extracted three times with 10 mL of dichloromethane. After the organic phase was removed under reduced pressure, a mixed solution of n-pentane / ethyl acetate (v / v=10 / 1) was added and ultrasonicated. A solid was obtained after centrifugation, and the residual solvent was removed in vacuo to obtain 35.3 mg of a light yellow solid with a yield of 25.7%. 1 H NMR (600MHz, (CD3)2SO) δ8.94 (dd, J=4.1, 1.4Hz, 1H), 8.46 (d, J=9.0Hz, 1H), 8.16(d,J=8.7Hz,1H),7.98(d,J=9.0Hz,1H),7.76(d,J=8.8Hz,2H),7.70(dd, J=8.4,4.1Hz,1H),7.33(d,J=8.8Hz,2H),2.33(s,2H),1.93(d,J=12.2Hz,4H) ,1.79(s,2H),1.66(s,4H),1.64(s,2H),1.43(s,9H).HRMS:m / z=704.12231[C 32 H 32 N6INa] + .

[0108] The schematic diagram of the synthesis process of the above Examples 13-15 compounds is shown in Figure 2 .

[0109] Example 16: Synthesis of Compound 16

[0110]

[0111] According to the synthesis method of Example 1, 8-amino-1,7-naphthyridine and 2,5-iodopyridine were used as raw materials to synthesize compound 16 to obtain 40.4 mg of white powder with a yield of 72.3%. 1H NMR (600MHz, CDCl3) δ9.86(s,1H),8.87(d,J=3.6Hz,1H),8.66(s,1H),8.53(s,1H),8.21(d,J=3.9Hz,1H),8.07(d,J =8.2Hz, 1H), 7.98 (dd, J = 8.8, 2.2Hz, 1H), 7.61 (dd, J = 8.0, 4.0Hz, 1H), 7.13 (d, J = 5.6Hz, 1H). HRMS: m / z = 348.99448 [C 13 H 10 N4I] + .

[0112] Example 17: Synthesis of Compound 17

[0113]

[0114] According to the synthesis method of Example 1, compound 17 was synthesized using 8-amino-1,7-naphthyridine and 2,5-diiodopyridine as raw materials to obtain 226.6 mg of yellow powder with a yield of 31.5%. 1 H NMR (400MHz, CDCl3) δ9.84(s,1H),8.86(dd,J=4.2,1.6Hz,1H),8.66(d,J=8.8Hz,1H),8.53(d,J=2.1Hz,1H),8.19(d,J=5.8Hz,1H), 8.07(dd,J=8.3,1.6Hz,1H),7.98(dd,J=8.8,2.3Hz,1H),7.61(dd,J=8.3,4.2Hz,1H),7.13(d,J=5.8Hz,1H).HRMS:m / z=348.99438[C 13 H 10 N4I] + .

[0115] Example 18: Synthesis of Compound 18

[0116]

[0117] According to the synthesis method of Example 1, compound 18 was synthesized using 8-amino-1,7-naphthyridine and 2,5-diiodopyrimidine as raw materials to obtain 58.1 mg of yellow powder with a yield of 49.0%. 1H NMR (400MHz, CDCl3) δ10.14(s,1H),8.88(d,J=4.2Hz,1H),8.80(s,2H),8.42(d,J=5.8Hz,1H),8 .11(d,J=8.3Hz,1H),7.63(dd,J=8.3,4.2Hz,1H),7.24(d,J=5.8Hz,1H).HRMS:m / z=349.98965[C 12 H9N5I] + .

[0118] Example 19: Synthesis of Labeled Precursor 19

[0119]

[0120] According to the synthesis method of Example 4, compound 16 was used as a raw material to synthesize the labeled precursor 19 to obtain 10.8 mg of a colorless oily product with a yield of 38.4%. 1 H NMR (400MHz, CDCl3) δ8.85(d,J=3.0Hz,1H),8.74(d,J=7.5Hz,1H),8.31(s,1H),8.18(d,J=5.8Hz,1H),8.03(dd,J=8.3,1.6Hz,1H),7.82(d,J=8.3Hz,1H ),7.57(dd,J=8.3,4.2Hz,1H),7.08(d,J=5.8Hz,1H),1.60–1.52(m,4H),1. 38–1.29(m,7H),1.14–1.09(m,4H),0.92–0.88(m,12H).MS:m / z=513.3406[C 25 H 37 N4Sn + .

[0121] Example 20: Synthesis of Labeled Precursor 20

[0122]

[0123] According to the synthesis method of Example 4, compound 17 was used as a raw material to synthesize the labeled precursor 20 to obtain 13.2 mg of a colorless oily product with a yield of 37.9%. 1H NMR (400MHz, CDCl3) δ9.77(s,1H),8.88(d,J=3.2Hz,1H),8.60(d,J=8.4Hz,1H),8.17(d,J=5.8Hz,1H),8.03(d,J=8.3Hz,1H),7.62–7.52 (m,2H),7.06(dd,J=11.8,6.2Hz,2H),1.68–1.57(m,4H),1.41–1.32(m,7H),1.18–1.10(m,6H),0.97–0.84(m,10H).MS:m / z=513.2824[C 25 H 37 N4Sn + .

[0124] Example 21: Synthesis of Labeled Precursor 21

[0125]

[0126] According to the synthesis method of Example 4, compound 18 was used as a raw material to synthesize the labeled precursor 21 to obtain 51.2 mg of a light yellow oily product with a yield of 14.3%. 1 H NMR (600MHz, CDCl3) δ10.06(s,1H),8.88–8.85(m,1H),8.65(s,2H),8.44(d,J=5.8Hz,1H),8.11–8.06(m,1H),7.61(dd,J=8.2,4. 2Hz,1H),7.19(d,J=5.8Hz,1H),1.60–1.52(m,4H),1.38–1.29(m,7H),1.14–1.09(m,6H),0.92–0.88(m,10H).MS:m / z=514.3310[C 24 H 36 N5Sn + .

[0127] Example 22: Synthesis of Compound 22

[0128]

[0129] According to the synthesis method of Example 1, compound 22 was synthesized using 1-naphthylamine and 2,5-iodopyridine as raw materials to obtain 68.6 mg of white powder with a yield of 59.4%. 1H NMR (600MHz, CDCl3) δ8.34(s,1H),8.01(d,J=8.1Hz,1H),7.90(d,J=7.8Hz,1H),7.75(d,J=8.1Hz,1H),7.6 0(dd,J=8.8,2.2Hz,1H),7.55–7.50(m,3H),7.50–7.46(m,1H),6.43–6.39(m,1H).HRMS:m / z=347.00397[C 15 H 12 N2I] + .

[0130] Example 23: Synthesis of Compound 23

[0131]

[0132] According to the synthesis method of Example 1, compound 23 was synthesized using 1-aminoisoquinoline and 2,5-iodopyridine as raw materials to obtain 24.5 mg of light yellow powder with a yield of 19.9%. 1 H NMR (400MHz, CDCl3) δ8.47 (s, 2H), 7.94 (d, J = 7.6Hz, 2H), 7.70 (d, J = 6.1Hz, 3H), 7.61 (d, J = 7.0Hz, 2H). HRMS: m / z = 347.99911 [C 14 H 11 N3I] + .

[0133] Example 24: Synthesis of Compound 24

[0134]

[0135] According to the synthesis method of Example 1, 8-aminoquinoline and 2,5-iodopyridine were used as raw materials to synthesize compound 24 to obtain 119.2 mg of white powder with a yield of 62.4%. 1 H NMR (600MHz, CDCl3) δ9.34(s,1H),8.82(dd,J=4.2,1.7Hz,1H),8.78(d,J=7.8Hz,1H),8.50(d,J=2.2Hz,1H),8.21(d,J=8.1Hz,1H),7.79(d d,J=8.7,2.3Hz,1H),7.57(t,J=8.0Hz,1H),7.49(dd,J=8.1,4.3Hz,1H),7.40(d,J=8.2Hz,1H),6.91(d,J=8.5Hz,1H).MS:m / z=347.9012[C 14 H 11 N3I]+ .

[0136] Example 25: Synthesis of Compound 25

[0137]

[0138] According to the synthesis method of Example 1, compound 25 was synthesized using 2,7-naphthyridin-1-amine and 2,5-iodopyridine as raw materials to obtain 50.0 mg of yellow powder with a yield of 41.1%. 1 H NMR (400MHz, (CD3)2SO) δ10.43(s,1H),9.89(s,1H),8.69(d,J=5.6Hz,1H),8.46(s,1H),8.30(t,J=7. 5Hz, 2H), 8.00 (d, J = 8.9Hz, 1H), 7.76 (d, J = 5.3Hz, 1H), 7.35 (d, J = 5.5Hz, 1H). HRMS: m / z = 348.99442 [C 13 H 10 N4I] + .

[0139] Example 26: Synthesis of Compound 26

[0140]

[0141] According to the synthesis method of Example 1, compound 26 was synthesized using 4-aminoquinazoline and 2,5-iodopyridine as raw materials to obtain 229.4 mg of light yellow powder with a yield of 67.3%. 1 H NMR (400MHz, (CD3)2SO) δ10.55(s,1H),8.73(s,1H),8.71(d,J=8.5Hz,1H),8.54(d,J=2.3Hz,1H),8.45(d,J =8.9Hz,1H),8.09(dd,J=8.9,2.4Hz,1H),7.93–7.82(m,2H),7.64(t,J=7.4Hz,1H).HRMS:m / z=348.99432[C 13 H 10 N4I] + .

[0142] Example 27: Synthesis of Labeled Precursor 27

[0143]

[0144] According to the synthesis method of Example 4, compound 22 was used as a raw material to synthesize the labeled precursor 27 to obtain 25.4 mg of a light yellow oily product with a yield of 36.1%. 1H NMR(400MHz, CDCl3)δ8.17(dd,J=1.8,0.9Hz,1H),8.12–8.07(m,1H),7.92–7.85 (m,1H),7.74–7.65(m,1H),7.59(dd,J=7.4,1.2Hz,1H),7.54–7.51(m,1H),7.51 –7.48(m,2H),7.47–7.44(m,1H),6.67(dt,J=8.1,1.3Hz,1H),1.60–1.48(m,4H) ,1.40–1.28(m,7H),1.07–0.97(m,4H),0.96–0.84(m,12H).MS:m / z=511.3610[C 27 H 39 N2Sn] + .

[0145] Example 28: Synthesis of Labeled Precursor 28

[0146]

[0147] According to the synthesis method of Example 4, compound 23 was used as a raw material to synthesize the labeled precursor 28 to obtain 17.2 mg of a light yellow oily product with a yield of 39.1%. 1 H NMR (600MHz, CDCl3) δ8.51(s,1H),8.25(s,1H),8.10(s,1H),7.87–7.66(m,4H),7.61(s,1H),7.18(s, 1H),1.59–1.50(m,4H),1.39–1.29(m,7H),1.12–1.05(m,4H),0.95–0.85(m,12H).MS:m / z=512.3503[C 26 H 38 N3Sn] + .

[0148] Example 29: Synthesis of Labeled Precursor 29

[0149]

[0150] According to the synthesis method of Example 4, compound 24 was used as a raw material to synthesize the labeled precursor 29 to obtain 42.6 mg of a light yellow oily product with a yield of 23.3%. 1H NMR (600MHz, CDCl3) δ9.15 (s, 1H), 8.83 (d, J = 7.8Hz, 1H), 8.79 (dd, J = 4.2, 1.6Hz, 1H) ,8.34(s,1H),8.12(dd,J=8.2,1.6Hz,1H),7.62(dd,J=8.0,1.7Hz,1H),7.53(t,J=8.0 Hz,1H),7.41(dd,J=8.2,4.2Hz,1H),7.32(s,1H),6.98(d,J=8.1Hz,1H),1.60–1.52( m,3H),1.39–1.31(m,8H),1.11–1.05(m,4H),0.96–0.87(m,12H).MS:m / z=512.3495[C 26 H 38 N3Sn] + .

[0151] Example 30: Synthesis of Labelled Precursor 30

[0152]

[0153] According to the synthesis method of Example 4, compound 25 was used as a raw material to synthesize the labeled precursor 30 to obtain 10.2 mg of a light yellow oily product with a yield of 13.9%. 1 H NMR(600MHz, CDCl3)δ8.72(s,2H),8.25(s,2H),7.85(s,1H),7.55(s,2H),7.18(s,1H),1.68 –1.48(m,3H),1.40–1.25(m,8H),1.17–1.00(m,4H),0.94–0.86(m,12H).MS:m / z=513.3484[C 25 H 37 N4Sn + .

[0154] Example 31: Synthesis of Labeled Precursor 31

[0155]

[0156] According to the synthesis method of Example 4, compound 26 was used as a raw material to synthesize the labeled precursor 31 to obtain 22.6 mg of a light yellow oily product with a yield of 23.3%. 1H NMR(400MHz, (CD3)2SO) δ10.32(s,1H),8.69(s,2H),8.37(d,J=2.5Hz,2H),7.96–7.86(m,2H),7.82(d,J=7.8Hz,1H),7 .62(t,J=7.4Hz,1H),1.63–1.45(m,3H),1.37–1.26(m,8H),1.12–1.07(m,4H),0.92–0.83(m,12H).MS:m / z=513.3434[C 25 H 37 N4Sn + .

[0157] The schematic diagram of the synthesis process of the above Examples 16-31 compounds is shown in Figure 3 .

[0158] Example 32: Synthesis of Compound 32

[0159]

[0160] 2-Chlorothiazolo[4,5-c]pyridine (173.2 mg, 1 mmol) and 4-iodoaniline (265.2 mg, 1.2 mmol) were reacted at 100°C for 3 hours. After the reaction was completed, methanol was added and filtered. The methanol was removed by vacuum distillation and separated by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 70.9 mg of a yellow solid product with a yield of 20.1%. 1 H NMR (600MHz, CD3OD) δ8.74 (s, 1H), 8.21 (d, J = 5.3Hz, 1H), 7.81 (d, J = 5.4Hz, 1H), 7.67 (d, J = 8.6Hz, 2H), 7.60 (d, J = 8.9Hz, 2H). MS: m / z = 354.1072 [C 12 H9IN3S] + .

[0161] Example 33: Synthesis of Compound 33

[0162]

[0163] According to the synthesis method of Example 32, compound 33 was synthesized using three equivalents of 2-chlorobenzoxazole and 4-iodoaniline as raw materials. After the reaction was completed, methanol was added, the mixture was filtered, and the solvent was removed under reduced pressure to obtain 886.0 mg of a white solid with a yield of 88.0%. 1H NMR (600MHz, CDCl3) δ7.73–7.67(m,2H),7.50(d,J=7.9Hz,1H),7.42(d,J=8.7Hz,2H) ,7.37(d,J=8.0Hz,1H),7.27(t,J=7.7Hz,1H),7.20–7.15(m,1H).MS:m / z=337.0947[C 13 H 10 IN2O] + .

[0164] Example 34: Synthesis of Compound 34

[0165]

[0166] 2-aminobenzothiazole (148.5 mg, 1 mmol), 1,4-diiodobenzene (329.1 mg, 1 mmol), anhydrous copper acetate (18.3 mg, 0.1 mmol), o-phenanthroline (35.8 mg, 0.2 mmol), cesium carbonate (488.1 mg, 1.5 mmol) were dissolved in dimethyl sulfoxide and reacted at 90°C for 18 hours. After the reaction was completed, water was added and extracted three times with ethyl acetate. The organic phase was dried with anhydrous sodium sulfate, and the organic solvent was removed by vacuum distillation. After separation by column chromatography (petroleum ether: ethyl acetate = 6:1), 113.0 mg of a white solid product was obtained with a yield of 32.1%. 1 H NMR (600MHz, CDCl3) δ7.58–7.54(m,3H),7.53–7.49(m,1H),7.37(dd,J=8.1,1.4Hz,1 H),7.14(tt,J=7.6,1.1Hz,1H),6.85(s,1H),6.77–6.73(m,2H).MS:m / z=351.9531[C 13 H9IN2S] - .

[0167] Example 35: Synthesis of Compound 35

[0168]

[0169] 2-aminobenzoxazole (668.9 mg, 5 mmol), 2,5-dibromopyridine (1183.5 mg, 5 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (290.6 mg, 0.5 mmol), tris(dibenzylideneacetone)dipalladium (228.0 mg, 0.25 mmol), cesium carbonate (2447.4 mg, 7.5 mmol) were dissolved in 1,4-dioxane, nitrogen was protected, and the reaction was carried out at 90°C for 18 hours. After the reaction was completed, the insoluble matter was removed by suction filtration, the solvent was removed under reduced pressure, 20 mL of ethyl acetate was added, a white solid precipitated, and the product was obtained by suction filtration. 932.0 mg, yield 64.3%. 1 H NMR(600MHz, (CD3)2SO) δ11.49(s,1H),8.45(d,J=2.5Hz,1H),8.28(d,J=9.0Hz,1H),8.09(dd, J=9.0,2.6Hz,1H),7.53(dd,J=15.1,7.9Hz,2H),7.26(t,J=7.6Hz,1H),7.19(t,J=7.7Hz,1H).

[0170] Example 36: Synthesis of Compound 36

[0171]

[0172] 2-aminobenzothiazole (186.7 mg, 1.2 mmol), 2,5-diiodopyridine (335.7 mg, 1 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (120.1 mg, 0.2 mmol), tri(dibenzylideneacetone)dipalladium (93.3 mg, 0.1 mmol), sodium carbonate (156.5 mg, 1.4 mmol) were dissolved in 8 ml of toluene, nitrogen was protected, and the reaction was carried out at 100°C for 24 hours. After the reaction was completed, water was added, and the mixture was extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and then separated by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain 29.8 mg of a white solid product with a yield of 8.5%. 1 H NMR(600MHz,(CD3)2SO)δ11.66(s,1H),8.62–8.45(m,1H),8.15–7.99(m,1H),7.90(d,J=7.9Hz,1H),7.63 (d,J=8.1Hz,1H),7.37(t,J=7.6Hz,1H),7.20(t,J=7.5Hz,1H),7.08(d,J=8.7Hz,1H).MS:m / z=352.9484[C 13 H9IN2S] - .

[0173] Example 37: Synthesis of Compound 37

[0174]

[0175] 2-Chlorobenzimidazole (464.2 mg, 3 mmol) and p-bromoaniline (510.0 mg, 3 mmol) were reacted at 120° C. for 3 hours. After the reaction was completed, the product was directly used to prepare compound 46.

[0176] Example 38: Synthesis of Compound 38

[0177]

[0178] According to the synthesis method of Example 37, compound 38 was synthesized using 1.5 equivalents of 2-chlorobenzimidazole and 4-iodoaniline as raw materials. After the reaction was completed, methanol was added and the mixture was filtered off. The solvent was removed under reduced pressure and separated by column chromatography (ethyl acetate: methanol = 1:1) to obtain 290.6 mg of a blue solid product with a yield of 58.0%. 1 H NMR (600MHz, CD3OD) δ7.71–7.66(m,2H),7.37–7.30(m,2H),7.29–7.23(m,2H),7.14(dt,J=6.3,3.4Hz,2H).MS:m / z=336.1238[C 13 H 11 IN3] + The schematic diagram of the synthesis process of the compounds of Examples 32-38 above is shown in Figure 4 .

[0179] Example 39: Synthesis of Labelled Precursor 39

[0180]

[0181] According to the synthesis method of Example 4, compound 32 was used as a raw material to synthesize the labeled precursor 39. After the reaction was completed, the solvent was removed under reduced pressure, and the residue was separated by chromatography column (petroleum ether: ethyl acetate = 1:4) to obtain 13.4 mg of colorless oily product with a yield of 8.0%. 1 H NMR (600MHz, CD3OD) δ8.75(s,1H),8.21(d,J=5.3Hz,1H),7.81(d,J=5.3Hz,1H),7.74–7.68(m,2H),7.51–7. 41(m,2H),1.61–1.56(m,4H),1.39–1.32(m,7H),1.10–1.07(m,4H),0.95–0.88(m,12H).MS: m / z=518.2894[C 24 H 36N3SSn] + .

[0182] Example 40: Synthesis of Labelled Precursor 40

[0183]

[0184] According to the synthesis method of Example 4, compound 33 was used as a raw material to synthesize the labeled precursor 40 to obtain 9.1 mg of a colorless oily product with a yield of 18.2%. 1 H NMR (400MHz, CDCl3) δ7.62–7.56(m,2H),7.53–7.46(m,3H),7.36(dd,J=8.0,2.7Hz,1H),7.24(dd,J=7.7,2.7Hz,1H),7.14 (td,J=7.7,2.6Hz,1H),1.71-1.45(m,4H),1.40-1.19(m,7H),1.14-0.96(m,4H),0.96–0.73(m,12H).MS:m / z=500.3674[C 25 H 37 N2OSn] + .

[0185] Example 41: Synthesis of Labelled Precursor 41

[0186]

[0187] According to the synthesis method of Example 4, compound 34 was used as a raw material to synthesize the labeled precursor 41 to obtain 3.6 mg of a colorless oily product with a yield of 7.0%. 1 H NMR (400MHz, CDCl3) δ7.59(d,J=7.7Hz,1H),7.49(t,J=7.9Hz,1H),7.44–7.29(m,3H),7.12(t,J=7.6Hz,1H),6.97( d,J=7.6Hz,2H),1.63-1.41(m,4H),1.40-1.22(m,8H),1.14-0.95(m,5H),0.92-0.80(m,10H).MS:m / z=516.7299[C 25 H 37 N2SS + .

[0188] Example 42: Synthesis of Labelled Precursor 42

[0189]

[0190] According to the synthesis method of Example 4, compound 35 was used as a raw material to synthesize the labeled precursor 42 to obtain 85.0 mg of a colorless oily product with a yield of 17.0%. 1 H NMR(600MHz, CDCl3)δ7.82(s,1H),7.60–7.47(m,1H),7.39(dd,J=8.0,2.1Hz,1H),7.31–7.21(m,3H),7.17(t,J =7.7Hz,1H),1.58–1.54(m,4H),1.40-1.22(m,6H),1.20-1.03(m,5H),0.94-0.79(m,12H).MS:m / z=502.2847[C 24 H 36 N3OSn] + .

[0191] Example 43: Synthesis of Labelled Precursor 43

[0192]

[0193] According to the synthesis method of Example 4, compound 36 was used as a raw material to synthesize the labeled precursor 43 to obtain 3.2 mg of a colorless oily product with a yield of 3.2%. 1 H NMR(400MHz, CDCl3)δ8.39(s,1H),7.79(dd,J=7.9,1.3Hz,1H),7.75–7.67(m,1H),7.67–7.59(m,1H),7.40(ddd,J=8.3,7.2,1.3Hz,1H), 7.25–7.19(m,1H),7.00–6.85(m,1H),1.57–1.50(m,4H),1.35–1.32(m,7H),1.09–1.05(m,4H),0.90–0.87(m,12H).MS:m / z=517.3007[C 24 H 36 N3SSn] + .

[0194] Example 44: Synthesis of Labelled Precursor 44

[0195]

[0196] According to the synthesis method of Example 4, compound 37 was used as a raw material to synthesize the labeled precursor 44 to obtain 112.5 mg of a colorless oily product with a yield of 7.5%. 1H NMR (400MHz, CDCl3) δ7.42–7.38(m,2H),7.34–7.30(m,2H),7.28–7.24(m,2H),7.06(dd,J=5.8,3.2Hz, 2H),1.57–1.49(m,4H),1.37–1.28(m,7H),1.07–1.01(m,4H),0.98–0.85(m,12H).MS: m / z=500.3674[C 25 H 38 N3Sn] + .

[0197] Example 45: Synthesis of Compound 45

[0198]

[0199] The labeled precursor 42 (29.8 mg, 0.06 mmol) and iodine (33 mg, 0.12 mmol) were dissolved in 5 ml of acetonitrile and reacted at room temperature for 4 h. After the reaction was completed, dichloromethane was added to the reaction system and filtered to obtain 3.0 mg of light yellow flocculent product with a yield of 14.9%. 1 H NMR(600MHz,(CD3)2SO)δ11.44(s,1H),8.54(dd,J=2.1,1.0Hz,1H),8.21–8.14(m,2H),7.55 –7.49(m,2H),7.26(td,J=7.7,1.1Hz,1H),7.18(td,J=7.7,1.2Hz,1H).MS:m / z=336.1797[C 25 H 38 N3Sn] + .

[0200] The schematic diagram of the synthesis process of the above Examples 39-45 compounds is shown in Figure 5 .

[0201] Example 46: Synthesis of Compound 46

[0202]

[0203] The compound 4-iodophenol (211.3 mg, 1 mmol), 2-bromopyridine (162.1 mg, 1 mmol) and potassium tert-butoxide (236.8 mg, 2 mmol) were dissolved in 6 mL DMSO and then heated in an oil bath at 100°C overnight. After the reaction was completed, water was added and extracted three times with dichloromethane. After distillation under reduced pressure to remove dichloromethane, column chromatography was used for separation (ethyl acetate: petroleum ether = 1:5) to obtain 150.1 mg of a colorless oily product with a yield of 49.2%. 1H NMR (400MHz, CDCl3) δ8.19 (dd, J=5.0, 2.0Hz, 1H), 7.69 (d, J=8.4Hz, 3H), 7.01 (dd, J=7.2, 5.0Hz, 1H), 6.92 (dd, J=8.6, 4.8Hz, 3H). HRMS: m / z=297.97177[C 11 H9ONI] + .

[0204] Example 47: Synthesis of Labelled Precursor 47

[0205]

[0206] According to the synthesis method of Example 4, compound 46 was used as a raw material to synthesize the labeled precursor 47 to obtain 13.1 mg of a light yellow oily product with a yield of 11.2%. 1 H NMR (600MHz, CDCl3) δ8.22(dd,J=5.0,2.0Hz,1H),7.69–7.66(m,1H),7.48(d,J=8.3Hz,2H),7.11(d,J=8.3Hz,2H),6.98(dd,J=7.1 ,5.0Hz,1H),6.90(d,J=8.3Hz,1H),1.58–1.53(m,4H),1.35(m,7H),1.09–1.02(m,4H),0.93–0.88(m,12H).HRMS:m / z=462.18146[C 23 H 36 ONSn] + .

[0207] Example 48: Synthesis of Compound 48

[0208]

[0209] The compound 4-iodophenol (622.3 mg, 3 mmol) and sodium hydride (420.9 mg, 10 mmol) were dissolved in 10 mL of anhydrous DMF. After stirring at room temperature for 1 hour, 4-bromopyridine (483.4 mg, 3 mmol) was added and heated at 140°C for 2 hours. After the reaction was completed, water was added and extracted with dichloromethane three times. After dichloromethane was removed by vacuum distillation, column chromatography (ethyl acetate: petroleum ether = 1:1) was used to obtain 357.1 mg of a white oily product with a yield of 40.9%. 1H NMR (600MHz, CDCl3) δ8.48(d,J=6.0Hz,2H),7.54(d,J=8.8Hz,2H),6.99(d,J=8.8Hz,2H),6.84(d,J=6.3Hz,2H).HRMS: m / z=297.97232[C 11 H9ONI] + .

[0210] Example 49: Synthesis of Labelled Precursor 49

[0211]

[0212] According to the synthesis method of Example 4, compound 48 was used as a raw material to synthesize the labeled precursor 49 to obtain 18.8 mg of a light yellow solid with a yield of 21.4%. 1 H NMR (400MHz, CDCl3) δ8.45(d,J=6.3Hz,2H),7.50(d,J=8.3Hz,2H),7.06(d,J=8.3Hz,2H),6.85(d,J=6.3H z,2H),1.59–1.51(m,5H),1.41–1.29(m,6H),1.09–1.03(m,5H),0.97–1.51(m,11H).MS:m / z=462.3629[C 23 H 36 ONSn] + .

[0213] Example 50: Synthesis of Compound 50

[0214]

[0215] According to the synthesis method of Example 1, compound 50 was synthesized using 2-aminopyridine and 1,4-diiodobenzene as raw materials to obtain 331.2 mg of a white solid with a yield of 56.6%. 1 H NMR (600MHz, CDCl3) δ8.21(dd,J=5.0,1.7Hz,1H),7.60(d,J=8.5Hz,2H),7.52(td,J=8.4,1.8Hz,1H),7.17 (d,J=8.6Hz,2H),6.81(d,J=8.4Hz,1H),6.77(dd,J=7.2,5.0Hz,1H),6.52(s,1H).HRMS:m / z=296.98834[C 11 H 10 N2I] + .

[0216] Example 51: Synthesis of Compound 51

[0217]

[0218] According to the synthesis method of Example 1, compound 51 was synthesized using aniline and 2,5-iodopyridine as raw materials to obtain 335.5 mg of a light yellow solid with a yield of 39.2%. 1 H NMR (600MHz, CDCl3) δ8.12(s,1H),7.31(q,J=8.6,7.9Hz,4H),7.07(d,J=7.9Hz,2H),7.03(t,J=7.3Hz,1H).HRMS: m / z=296.98832[C 11 H 10 N2I] + .

[0219] Example 52: Synthesis of Compound 52

[0220]

[0221] According to the synthesis method of Example 1, compound 52 was synthesized using 2-aminopyridine and 2,5-iodopyridine as raw materials to obtain 77.2 mg of a white solid with a yield of 49.9%. 1 H NMR(600MHz, CDCl3)δ8.42(d,J=1.9Hz,1H),8.27–8.24(m,1H),7.85–7.82(m,1H),7.62(t,J=7 .7Hz,1H),7.56–7.52(m,1H),7.44(d,J=8.5Hz,1H),6.90–6.86(m,1H).HRMS:m / z=297.98355[C 10 H9N3I] + .

[0222] Example 53: Synthesis of Labelled Precursor 53

[0223]

[0224] According to the synthesis method of Example 4, compound 50 was used as a raw material to synthesize the labeled precursor 53 to obtain 18.1 mg of a light yellow oily product with a yield of 27.2%. 1H NMR (400MHz, CDCl3) δ8.18(d,J=4.7Hz,1H),7.53–7.45(m,1H),7.42(d,J=8.1Hz,2H),7.29(d,J=8.1Hz,2H),6.91(d,J=8.4Hz,1H),6 .76–6.71(m,1H),6.69(s,1H),1.69–1.51(m,5H),1.47–1.23(m,6H),1.11–1.01(m,4H),0.94–0.87(m,12H).HRMS:m / z=461.19736[C 23 H 37 N2Sn] + .

[0225] Example 54: Synthesis of Labelled Precursor 54

[0226]

[0227] According to the synthesis method of Example 4, compound 51 was used as a raw material to synthesize the labeled precursor 54 to obtain 33.0 mg of a white oily product with a yield of 18.1%. 1 H NMR (600MHz, CDCl3) δ8.58(d,J=2.1Hz,1H),7.32–7.27(m,4H),7.09(d,J=7.7Hz,2H),6.98(t,J=7.4Hz ,1H),1.60–1.49(m,5H),1.38–1.28(m,6H),1.16–1.09(m,4H),0.92–0.85(m,12H).MS: m / z=461.3762[C 23 H 37 N2Sn] + .

[0228] Example 55: Synthesis of Labelled Precursor 55

[0229]

[0230] According to the synthesis method of Example 4, compound 52 was used as a raw material to synthesize the labeled precursor 55 to obtain 11.4 mg of a light yellow oily product with a yield of 18.4%. 1H NMR (600MHz, CDCl3) δ8.25(dt,J=5.0,1.4Hz,1H),8.23(s,1H),7.66(d,J=8.0Hz,1H),7.61(d,J=6.4Hz,2H),7.49(s,1H),6 .85(t,J=5.5Hz,1H),1.57–1.50(m,4H),1.39–1.29(m,7H),1.09–1.05(m,4H),0.95–0.86(m,12H).HRMS:m / z=462.19254[C 22 H 36 N3Sn] + .

[0231] Example 56: Synthesis of Compound 56

[0232]

[0233] According to the synthesis method of Example 7, 3-aminopyridine (201.1 mg, 2 mmol) and sodium hydride (199.4 mg, 5 mmol) were used as raw materials to obtain 210.9 mg of a light yellow solid with a yield of 36.7%. 1 H NMR(600MHz, (CD3)2SO) δ9.38(s,1H),8.75(d,J=2.6Hz,1H),8.35(d,J=2.3Hz,1H),8.14(d,J=8.3Hz,1H),8.11(d,J =4.6Hz,1H),7.87(dd,J=8.7,2.3Hz,1H),7.29(dd,J=8.3,4.6Hz,1H),6.76(d,J=8.7Hz,1H).HRMS:m / z=297.98328[C 10 H9N3I] + .

[0234] Example 57: Synthesis of Labeled Precursor 57

[0235]

[0236] According to the synthesis method of Example 4, compound 56 was used as a raw material to synthesize the labeled precursor 57 to obtain 13.1 mg of a light yellow oily product with a yield of 24.0%. 1H NMR (600MHz, CDCl3) δ8.60(d,J=2.4Hz,1H),8.29(d,J=3.7Hz,1H),8.16(s,1H),7.98(d,J=8.6Hz,1H),7.67–7.59(m,1H),7.28(dd,J=8 .2,4.7Hz,1H),6.83(d,J=8.1Hz,1H),1.57–1.50(m,4H),1.39–1.29(m,7H),1.09–1.05(m,4H),0.95–0.86(m,12H).MS:m / z=460.2707[C 22 H 36 N3Sn] + .

[0237] Example 58: Synthesis of Compound 58

[0238]

[0239] According to the synthesis method of Example 7, compound 58 was synthesized using 4-aminopyridine and 2-bromo-5-iodopyridine as raw materials to obtain 379.3 mg of a white solid with a yield of 65.3%. 1 H NMR (600MHz, (CD3)2SO) δ9.79 (s, 1H), 8.46 (d, J = 2.1Hz, 1H), 8.33 (d, J = 5.6Hz, 2H), 7.97 (d d,J=8.7,2.3Hz,1H),7.64(d,J=6.1Hz,2H),6.83(d,J=8.7Hz,1H).HRMS:m / z=297.98322[C 10 H9N3I] + .

[0240] Example 59: Synthesis of Compound 59

[0241]

[0242] According to the synthesis method of Example 7, compound 59 was synthesized using 2-methyl-4-aminopyridine and 2-bromo-5-iodopyridine as raw materials to obtain 255.2 mg of a light pink solid with a yield of 68.3%. 1H NMR(600MHz, (CD3)2SO) δ9.57(s,1H),8.44(d,J=2.2Hz,1H),8.18(d,J=5.7Hz,1H),7.93(dd,J=8.7,2.3Hz,1H) ,7.45(d,J=1.9Hz,1H),7.43(dd,J=5.6,2.1Hz,1H),6.81(d,J=8.7Hz,1H),2.37(s,3H).HRMS:m / z=311.99902[C 11 H 11 N3I] + .

[0243] Example 60: Synthesis of Labelled Precursor 60

[0244]

[0245] According to the synthesis method of Example 4, compound 58 was used as a raw material to synthesize the labeled precursor 60 to obtain 13.5 mg of a light yellow oily product with a yield of 17.7%. 1 H NMR (400MHz, CDCl3) δ8.37(d,J=6.4Hz,2H),8.30(dd,J=1.6,0.9Hz,1H),7.65(dd,J=8.0,1.7Hz,1H),7.45(d,J=5.3Hz,2H),7.32( s,1H),6.94(d,J=8.0Hz,1H),1.59–1.49(m,4H),1.38–1.28(m,7H),1.10–1.04(m,4H),0.92–0.87(m,12H).HRMS:m / z=462.19266[C 22 H 36 N3Sn] + .

[0246] Example 61: Synthesis of Compound 61

[0247]

[0248] Compound 59 (254.9 mg, 0.8 mmol) and di-tert-butyl dicarbonate (1.6 g, 7.5 mmol) were dissolved in 10 mL of dioxane, triethylamine (76.1 mg, 0.75 mmol) was added, and the mixture was reacted at 90°C overnight. The solvent was removed under reduced pressure, and the mixture was separated by column chromatography (ethyl acetate: petroleum ether = 4:1) to obtain 301.7 mg of a white solid with a yield of 89.9%. This solid was used as a raw material to synthesize compound 61 to obtain 375.2 mg of a white oily product with a yield of 91.3%. 1H NMR (600MHz, CDCl3) δ8.64 (s, 1H), 8.43–8.36 (m, 1H), 8.06 (d, J = 8.3Hz, 1H), 7.24 (s,1H),7.01(s,1H),6.91(s,1H),2.55(s,3H),1.46(s,9H).MS:m / z=412.2649[C 16 H 19 IN3O2] + .

[0249] Example 62: Synthesis of Labeled Precursor 62

[0250]

[0251] According to the synthesis method of Example 4, compound 61 was used as a raw material to synthesize the labeled precursor 62 to obtain 34.4 mg of a white oily product with a yield of 23.6%. 1 H NMR (600MHz, CDCl3) δ8.45(s,1H),8.36(d,J=5.7Hz,1H),7.83(d,J=7.7Hz,1H),7.30(d,J=7.7Hz,1H),7.04(s,1H),6.90(d,J=5.6H z,1H),2.51(s,3H),1.57–1.50(m,4H),1.43(s,9H),1.37–1.30(m,7H),1.13–1.08(m,4H),0.94–0.85(m,12H).MS:m / z=576.2248[C 28 H 46 N3O2Sn] + .

[0252] Example 63: Synthesis of Compound 63

[0253]

[0254] 4-Methoxypyridine (110.1 mg, 1 mmol) and 4-iodoaniline (264.4 mg, 1.2 mmol) were dissolved in 5 mL of tetrahydrofuran, and 1.5 mL of potassium bis(trimethylsilyl)amide (1 M tetrahydrofuran solution) was added. The mixture was reacted at 110° C. for 5 hours. After the reaction was completed, the insoluble matter was removed by suction filtration, and the solvent was removed by distillation under reduced pressure. The mixture was separated by column chromatography (dichloromethane:methanol=6:1) to obtain 177.3 mg of a light yellow solid with a yield of 61.1%. 1H NMR (600MHz, (CD3)2SO) δ8.90 (s, 1H), 8.20 (d, J = 6.3Hz, 2H), 7.63 (d, J = 8.7Hz, 2H), 7.02 (d, J = 8.7Hz, 2H), 6.91 (d, J = 6.3Hz, 2H). HRMS: m / z = 296.98825 [C 11 H 10 N2I] + .

[0255] Example 64: Synthesis of Compound 64

[0256]

[0257] According to the synthesis method of Example 63, compound 64 was synthesized using 4-methoxy-2-methylpyridine and 4-iodoaniline as raw materials to obtain 210.3 mg of a light grey solid product with a yield of 35.8%. 1 H NMR (600MHz, (CD3)2SO) δ8.87 (s, 1H), 8.09 (d, J = 5.7Hz, 1H), 7.63 (d, J = 8.6Hz, 2H), 7.01 (d, J = 8. 6Hz, 2H), 6.78 (d, J=2.0Hz, 1H), 6.74 (dd, J=5.7, 2.2Hz, 1H), 2.33 (s, 3H). HRMS: m / z=311.00391[C 12 H 12 N2I] + .

[0258] Example 65: Synthesis of Compound 65

[0259]

[0260] According to the synthesis method of Example 61, compound 65 was synthesized from compound 63 to obtain 109.3 mg of a white solid product with a yield of 89.4%. 1H NMR (600 MHz, CDCl3) δ 8.45 (d, J = 6.2 Hz, 2H), 7.73 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 6.4 Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 1.44 (s, 9H). MS: m / z = 397.3304 [C 16 H 18 IN2O2] + .

[0261] Example 66: Synthesis of Compound 66

[0262]

[0263] According to the synthesis method of Example 61, compound 66 was synthesized using compound 64 as raw material to obtain 122.8 mg of white solid product with a yield of 86.0%. 1 H NMR (600MHz, CDCl3) δ8.33(d,J=5.7Hz,1H),7.72(d,J=8.6Hz,2H),7.02(d,J=2 .0Hz,1H),6.92(d,J=8.6Hz,3H),2.49(s,3H),1.44(s,9H).MS:m / z=410.6138[C 17 H 20 IN2O2] + .

[0264] Example 67: Synthesis of Labeled Precursor 67

[0265]

[0266] According to the synthesis method of Example 4, compound 65 was used as the raw material to synthesize the labeled precursor 67 to obtain 34.4 mg of a white oily product with a yield of 23.6%. 1H NMR (600 MHz, CDCl3) δ8.42 (d, J = 5.9 Hz, 2H), 7.49 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 6.3 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 1.57-1.49 (m, 4H), 1.43 (s, 9H), 1.38-1.29 (m, 7H), 1.09-1.04 (m, 4H), 0.91-0.85 (m, 12H). MS: m / z = 561.3700 [C 28 H 45 N2O2Sn] + .

[0267] Example 68: Synthesis of Labeled Precursor 68

[0268]

[0269] According to the synthesis method of Example 4, compound 66 was used as a raw material to synthesize the labeled precursor 68 to obtain 9.9 mg of a light yellow oily product with a yield of 29.3%. 1H NMR (600MHz, CDCl3) δ8.31(d,J=5.8Hz,1H),7.48(d,J=6.5Hz,2H),7.09(s,3H),6.94(d,J=5.7Hz,1H),2.49(s,3H ),1.58–1.49(m,4H),1.43(s,9H),1.38–1.29(m,7H),1.11–1.05(m,4H),0.94–0.85(m,12H).MS: m / z=575.1126[C 29 H 47 N2O2Sn] + .

[0270] Example 69: Synthesis of Compound 69

[0271]

[0272] 4-Methylaminopyridine (391.3 mg, 3.6 mmol), 2-bromo-5-iodopyridine (845.5 mg, 3 mmol), potassium tert-butoxide (673.4 mg, 6 mmol), tris(dibenzylideneacetone)dipalladium (179.0 mg, 0.2 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (232.4 mg, 0.4 mmol) were dissolved in 15 mL of dioxane and protected with nitrogen at 110° C. overnight. After completion of the reaction, the solvent was distilled off under reduced pressure and separated by column chromatography (ethyl acetate: methanol = 10:1) to obtain 465.9 mg of a light yellow solid with a yield of 50.4%. 1 H NMR (400MHz, CDCl3) δ8.55(d,J=2.1Hz,1H),8.42(d,J=6.1Hz,2H),7.81(dd,J=8.7,2.3H z,1H),7.05(d,J=6.4Hz,2H),6.95(d,J=8.7Hz,1H),3.50(s,3H).HRMS:m / z=311.99875[C 10 H9N3I] + .

[0273] Example 70: Synthesis of Labelled Precursor 70

[0274]

[0275] According to the synthesis method of Example 4, compound 69 was used as a raw material to synthesize the labeled precursor 70 to obtain 41.2 mg of a yellow oily product with a yield of 26.9%. 1H NMR (400MHz, CDCl3) δ8.40(s,1H),8.36(d,J=5.2Hz,2H),7.55(t,J=7.2Hz,1H),7.12(d,J=8.0Hz,1H),7.00(d,J=5.8H z,2H),3.51(s,3H),1.60–1.49(m,4H),1.39–1.28(m,7H),1.12–1.04(m,4H),0.95–0.82(m,12H).MS:m / z=476.5998[C 23 H 38 N3Sn] + .

[0276] Example 71: Synthesis of Compound 71

[0277]

[0278] According to the synthesis method of Example 1, compound 71 was synthesized using 2,5-iodopyridine and 3-aminopyridazine as raw materials to obtain 76.3 mg of yellow powder with a yield of 39.1%. 1 H NMR (400MHz, CDCl3) δ8.78(d,J=4.1Hz,1H),8.45(s,1H),8.39(d,J=9.0Hz,1H),7.90(d,J=8. 7Hz, 1H), 7.49 (d, J=8.8Hz, 1H), 7.43 (dd, J=8.3, 3.7Hz, 1H). HRMS: m / z=298.97891[C9H8N4I] + .

[0279] Example 72: Synthesis of Compound 72

[0280]

[0281] According to the synthesis method of Example 1, compound 72 was synthesized using 2,5-iodopyridine and 4-aminopyrimidine as raw materials to obtain 24.3 mg of white powder with a yield of 26.7%. 1 H NMR (400MHz, CD3OD) δ8.67(s,1H),8.53–8.46(m,1H),8.34(d,J=6.2Hz,1H),8.00(dd,J=8. 7,2.2Hz,1H),7.72(d,J=6.6Hz,1H),7.58(d,J=8.9Hz,1H).HRMS:m / z=298.97879[C9H8N4I] + .

[0282] Example 73: Synthesis of Compound 73

[0283]

[0284] According to the synthesis method of Example 1, compound 73 was synthesized using 2,5-iodopyridine and 4-aminopyrazine as raw materials to obtain 59.9 mg of light yellow powder with a yield of 63.7%. 1 H NMR (400MHz, CD3OD) δ8.89(s,1H),8.42(s,1H),8.21(s,1H),8.01(s,1H),7.92(d,J=8.8Hz,1H),7.55(d,J=8.8Hz,1H).HRMS: m / z=298.97876[C9H8N4I] + .

[0285] Example 74: Synthesis of Compound 74

[0286]

[0287] According to the synthesis method of Example 1, compound 74 was synthesized using 2,5-iodopyridine and 2-aminopyrimidine as raw materials to obtain 71.2 mg of light yellow powder with a yield of 45.4%. 1 H NMR (600MHz, CDCl3) δ8.53(d,J=4.8Hz,2H),8.52(d,J=2.1Hz,1H),8.32(d,J=8.8Hz,1 H),7.93(dd,J=8.7,2.4Hz,1H),6.84(t,J=4.8Hz,1H).HRMS:m / z=298.97888[C9H8N4I] + .

[0288] Example 75: Synthesis of Compound 75

[0289]

[0290] According to the synthesis method of Example 1, compound 75 was synthesized using 2-chloro-5-iodopyrimidine and 2-aminopyrimidine as raw materials to obtain 157.1 mg of yellow powder with a yield of 35.2%. 1 H NMR (600MHz, (CD3)2SO) δ10.23(s,1H),8.95(s,1H),8.78(s,1H),8.73(d,J=4.8Hz,2H),7.30(t,J=4.8Hz,1H).HRMS: m / z=299.97397[C8H7N5I] + .

[0291] Example 76: Synthesis of Labelled Precursor 76

[0292]

[0293] According to the synthesis method of Example 4, compound 71 was used as a raw material to synthesize the labeled precursor 76 to obtain 16.4 mg of a colorless oily product with a yield of 18.9%. 1 H NMR (400MHz, CDCl3) δ8.78(dd,J=4.6,1.4Hz,1H),8.38(d,J=9.5Hz,1H),8.19(d,J=5.2Hz,1H),7.79(s,1H),7. 45(s,2H),1.58–1.51(m,4H),1.37–1.28(m,7H),1.15–1.05(m,4H),0.99–0.83(m,12H).HRMS:m / z=463.18808[C 21 H 35 N4Sn + .

[0294] Example 77: Synthesis of Labeled Precursor 77

[0295]

[0296] According to the synthesis method of Example 4, compound 72 was used as the raw material to synthesize the labeled precursor 77 to obtain 11.2 mg of colorless oily product with a yield of 10.8%. 1 H NMR (400MHz, CDCl3) δ8.79(s,1H),8.45(d,J=5.9Hz,1H),8.25(s,1H),7.77(d,J=8.1Hz,1H),7.68(d,J=5.8Hz,1H) ,7.55(s,1H),1.60–1.48(m,4H),1.39–1.29(m,7H),1.12–1.06(m,4H),0.94–0.83(m,12H).HRMS:m / z=463.18802[C 21 H 35 N4Sn + .

[0297] Example 78: Synthesis of Labelled Precursor 78

[0298]

[0299] According to the synthesis method of Example 4, compound 73 was used as the raw material to synthesize the labeled precursor 78 to obtain 12.3 mg of a light yellow oily product with a yield of 33.2%. 1H NMR (400MHz, CDCl3) δ8.94(s,1H),8.26(s,1H),8.17(dd,J=2.7,1.5Hz,1H),8.11(d,J=2.6Hz,1H),7.72(d,J=8.1Hz,1H),7.62(d,J =8.0Hz,1H),1.61–1.48(m,6H),1.39–1.29(dt,J=14.4,7.3Hz,8H),1.11–1.06(m,5H),0.94–0.85(m,11H).HRMS:m / z=463.18808[C 21 H 35 N4Sn + .

[0300] Example 79: Synthesis of Labelled Precursor 79

[0301]

[0302] According to the synthesis method of Example 4, compound 74 was used as a raw material to synthesize the labeled precursor 79 to obtain 22.9 mg of a colorless oily product with a yield of 14.6%. 1 H NMR (400MHz, CDCl3) δ8.52(d,J=4.7Hz,2H),8.41(d,J=7.9Hz,1H),8.26(s,1H),7.80(d,J=8.2Hz,1H),6.83(t,J= 4.3Hz,1H),1.59–1.50(m,4H),1.39–1.23(m,7H),1.13–1.03(m,4H),0.96–0.84(m,12H).HRMS:m / z=463.18793[C 21 H 35 N4Sn + .

[0303] Example 80: Synthesis of Compound 80

[0304]

[0305] According to the synthesis method of Example 69, compound 80 was synthesized using 2-aminopyridine and 2-bromo-6-fluoropyridine as raw materials to obtain 29.3 mg of white powder with a yield of 56.1%. 1H NMR(400MHz, CDCl3)δ8.26(ddd,J=5.0,1.8,0.8Hz,1H),7.72–7.63(m,2H),7.59(d,J=8.4Hz,1H),7.42(dd ,J=8.0,2.0Hz,1H),6.91(ddd,J=7.1,5.1,1.1Hz,1H),6.46(dd,J=7.8,2.3Hz,1H).HRMS:m / z=190.07761[C 10 H9FN3] + .

[0306] Example 81: Synthesis of Compound 81

[0307]

[0308] According to the synthesis method of Example 69, compound 81 was synthesized using 2-aminopyridine and 2-bromo-5-fluoropyridine as raw materials to obtain 34.7 mg of white powder with a yield of 72.3%. 1 H NMR (400MHz, CDCl3) δ8.29–8.20(m,1H),8.11(d,J=2.5Hz,1H),7.73(dd,J=9.0,3.3Hz,1H),7 .61(t,J=7.1Hz,1H),7.39(dd,J=11.2,5.2Hz,2H),6.91–6.81(m,1H).HRMS:m / z=190.07761[C 10 H9N3F] + .

[0309] Example 82: Synthesis of Compound 82

[0310]

[0311] According to the synthesis method of Example 69, compound 82 was synthesized using 2-aminopyridine and 2-bromo-4-fluoropyridine as raw materials to obtain 22.8 mg of white powder with a yield of 63.3%. 1 H NMR (400MHz, (CD3)2SO) δ9.80 (s, 1H), 8.31 (d, J = 4.1Hz, 1H), 8.13 (s, 1H), 8.07 (d, J = 5.6Hz, 1H),7.71(t,J=7.7Hz,1H),7.50(d,J=5.6Hz,1H),7.03–6.87(m,2H).HRMS:m / z=190.07718[C 10 H9N3I] + .

[0312] Example 83: Synthesis of Compound 83

[0313]

[0314] According to the synthesis method of Example 69, compound 83 was synthesized using 2-aminopyrimidine and 2-bromo-5-fluoropyridine as raw materials to obtain 16.9 mg of white powder with a yield of 46.9%. 1 H NMR (400MHz, CDCl3) δ8.53(d,J=4.8Hz,2H),8.48(dd,J=9.3,4.0Hz,1H),8.21(d,J=3.0Hz,1 H),7.47(ddd,J=9.3,7.7,3.0Hz,1H),6.84(t,J=4.8Hz,1H).HRMS:m / z=191.07275[C9H8N4F] + .

[0315] Example 84: Synthesis of Compound 84

[0316]

[0317] According to the synthesis method of Example 7, compound 84 was synthesized using 4-aminopyridine and 2-bromo-6-fluoropyridine as raw materials to obtain 101.3 mg of light yellow powder with a yield of 48%. 1 H NMR(600MHz, (CD3)2SO) δ8.38(d,J=6.4Hz,2H),7.66(d,J=6.5Hz,2H),7.63(t,J= 7.9Hz,1H),7.16(d,J=7.5Hz,1H),6.98(d,J=8.1Hz,1H).HRMS:m / z=190.07726[C 10 H9N3F] + .

[0318] Example 85: Synthesis of Compound 85

[0319]

[0320] According to the synthesis method of Example 7, compound 85 was synthesized using 4-aminopyridine and 2-bromo-5-fluoropyridine as raw materials to obtain 53.8 mg of white powder with a yield of 39%. 1 H NMR (600MHz, CDCl3) δ8.36(d,J=6.4Hz,2H),8.19(d,J=3.0Hz,1H),7.46(d,J=6.4Hz,2H) ,7.38(ddd,J=8.9,7.7,3.0Hz,1H),7.00(dd,J=8.9,3.4Hz,1H).HRMS:m / z=190.07748[C 10H9N3F] + .

[0321] Example 86: Synthesis of Compound 86

[0322]

[0323] According to the synthesis method of Example 7, compound 86 was synthesized using 4-aminopyridine and 2-bromo-4-fluoropyridine as raw materials to obtain 37.7 mg of white powder with a yield of 43%. 1 H NMR (600MHz, (CD3)2SO) δ9.53 (s, 1H), 8.40 (d, J = 6.2Hz, 2H), 8.11 (d, J = 5.7Hz, 1H), 7.23 (d, J = 2.0Hz, 1H), 7.15 (t, J = 6.8Hz, 3H). HRMS: m / z = 190.07745 [C 10 H9N3F] + .

[0324] Example 87: Synthesis of Compound 87

[0325]

[0326] According to the synthesis method of Example 7, compound 87 was synthesized using 2-methyl-4-aminopyridine and 2-bromo-6-fluoropyridine as raw materials to obtain 64.7 mg of white powder with a yield of 40%. 1 H NMR (600MHz, CDCl3) δ8.27(d,J=5.7Hz,1H),7.43(t,J=7.9Hz,1H),7.33(d,J=6.1Hz,2 H),7.06(d,J=7.6Hz,1H),6.98(d,J=8.1Hz,1H),2.52(s,3H).HRMS:m / z=204.09294[C 11 H 11 N3F] + .

[0327] Example 88: Synthesis of Compound 88

[0328]

[0329] According to the synthesis method of Example 7, compound 88 was synthesized using 2-methyl-4-aminopyridine and 2-bromo-5-fluoropyridine as raw materials to obtain 89.0 mg of light gray powder with a yield of 68%. 1H NMR(600MHz, (CD3)2SO) δ9.53(s,1H),8.24(d,J=3.1Hz,1H),8.16(d,J=5.7Hz,1H),7.64(td,J=8.7,3.1Hz,1H ),7.46(s,1H),7.40(dd,J=5.7,2.0Hz,1H),6.97(dd,J=9.1,3.7Hz,1H),2.37(s,3H).HRMS:m / z=204.09323[C 11 H 11 N3F] + .

[0330] Example 89: Synthesis of Compound 89

[0331]

[0332] According to the synthesis method of Example 7, compound 89 was synthesized using 2-methyl-4-aminopyridine and 2-bromo-4-fluoropyridine as raw materials to obtain 118.4 mg of white powder with a yield of 61%. 1 H NMR (600MHz, CDCl3) δ8.36(d,J=5.6Hz,1H),8.16(d,J=5.7Hz,1H),7.21(d,J=2.0Hz,1H),6.97(dd ,J=5.7,2.1Hz,1H),6.91(s,1H),6.90(dd,J=5.6,2.1Hz,1H),2.53(s,3H).HRMS:m / z=204.09297[C 11 H 11 N3F] + .

[0333] Example 90: Synthesis of Compound 90

[0334]

[0335] According to the synthesis method of Example 1, compound 90 was synthesized using 2-aminopyridine and 2-bromopyridine-N-oxide as raw materials to obtain 104.7 mg of white powder with a yield of 34%. 1H NMR (600MHz, CDCl3) δ8.78(dd,J=8.6,1.7Hz,1H),8.35–8.29(m,1H),8.27(d,J=5.9Hz,1H),7.62(ddd,J=8.3,7.4,1.9 Hz,1H),7.31(ddd,J=8.8,7.6,1.5Hz,1H),6.97(d,J=8.2Hz,1H),6.93(ddd,J=7.2,5.0,0.7Hz,1H),6.81–6.75(m,1H).

[0336] Example 91: Synthesis of Compound 91

[0337]

[0338] Compound 90 (50.0 mg, 0.27 mmol) was dissolved in 10 mL of dichloromethane, and then trimethylamine (0.8 mL, 1.6 mmol) and trifluoroacetic anhydride (170.1 mg, 0.81 mmol) were added to the reaction solution in sequence and stirred at room temperature for half an hour. After the reaction was completed, 50 mL of water was added, and the mixture was extracted three times with 10 mL of dichloromethane. The aqueous phase was removed by vacuum distillation, and ether and acetonitrile were added for ultrasonic washing. Then, centrifugation was performed to obtain 37.2 mg of a brown-yellow solid in the lower layer with a yield of 40.4%. 1 H NMR(600MHz, (CD3)2SO) δ8.30(dd,J=4.9,1.8Hz,1H),8.00(t,J=8.1Hz,1H),7.83(d,J=8.3Hz,1H),7.77(td,J=8.1,7.5,2 .0Hz,1H),7.66(d,J=8.4Hz,1H),7.42(d,J=7.9Hz,1H),7.00(dd,J=7.2,4.9Hz,1H),3.57(s,9H).HRMS:m / z=229.14491[C 13 H 17 N4] + .

[0339] Example 92: Synthesis of Compound 92

[0340]

[0341] According to the synthesis method of Example 14, compound 92 was synthesized with compound 52 as the raw material to obtain 266.5 mg of white solid with a yield of 90.2%. 1H NMR (600MHz, CDCl3) δ8.52(d,J=2.2Hz,1H),8.39(dd,J=4.8,1.5Hz,1H),8.00(dd,J=8.6,2.3Hz,1H),7.76(td,J=7.9, 1.9Hz,1H),7.51(d,J=8.1Hz,1H),7.43(d,J=8.6Hz,1H),7.15(dd,J=7.3,5.0Hz,1H),1.44(s,9H).MS:m / z=398.8785[C 15 H 17 IN3O2] + .

[0342] Example 93: Synthesis of Compound 93

[0343]

[0344] According to the synthesis method of Example 14, compound 93 was synthesized from compound 58 to obtain 157.9 mg of a white oily product with a yield of 92%. 1H NMR (600 MHz, CDCl3) δ 8.63 (d, J = 2.3 Hz, 1H), 8.52 (dd, J = 4.8, 1.6 Hz, 2H), 8.06 (dd, J = 8.5, 2.3 Hz, 1H), 7.27 (s, 1H), 7.14-7.09 (m, 2H), 1.46 (s, 9H). MS: m / z = 397.6735 [C 15 H 17 IN3O2] + .

[0345] Example 94: Synthesis of Labelled Precursor 94

[0346]

[0347] According to the synthesis method of Example 15, compound 92 was used as a raw material to synthesize the labeled precursor 94 to obtain 64.9 mg of a light yellow solid with a yield of 10.3%. 1H NMR(600MHz, (CD3)2SO) δ8.56(d,J=2.3Hz,1H),8.37–8.31(m,1H),8.19(dd,J=8.7,2.3Hz,1H),7.87(td,J=7.8,1.8Hz,1H),7.67(d,J=8.7Hz, 1H),7.50(d,J=8.1Hz,1H),7.27(dd,J=7.3,4.9Hz,1H),2.31(s,2H),1.93(d,J=12.2Hz,4H),1.79(s,2H),1.39(s,9H).HRMS: m / z=654.10675[C 28 H 30 O6N3INa] + .

[0348] Example 95: Synthesis of Labeled Precursor 95

[0349]

[0350] Compound 93 (160.2 mg, 0.4 mmol), 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis(tetrafluoroborate) (351.1 mg, 1 mmol), and trimethylsilyl acetate (269.0 mg, 1.2 mmol) were dissolved in 10 mL of acetonitrile and reacted at room temperature overnight under nitrogen protection. After the reaction, the solvent was removed by distillation under reduced pressure, 30 mL of water was added, and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 10 mL of a 0.5 M sodium acetate / acetic acid mixed solution. The organic phase was removed by distillation under reduced pressure, and n-pentane / dichloromethane (v / v=10 / 1) was added and ultrasonicated to obtain a solid, and the residual solvent in the solid was removed with an oil pump. The solid obtained in the first step was dissolved in 10 mL of ethanol, and 6.10-dioxaspiro[4.5]decan-7,9-dione was added to a saturated sodium carbonate solution, and the ethanol solution was added dropwise together, and the pH value of the solution was adjusted to be greater than 10. The reaction was completed at room temperature for 30 minutes, 30 mL of water was added, and extraction was performed three times with 10 mL of dichloromethane. After the organic phase was removed by vacuum distillation, a mixed solution of n-pentane / ethyl acetate (v / v=10 / 1) was added and ultrasonicated. A solid was obtained after centrifugation. The residual solvent in the solid was removed by an oil pump to obtain 129.2 mg of a light yellow solid with a yield of 57%. 1H NMR(400MHz, (CD3)2SO) δ8.64(d,J=2.2Hz,1H),8.52(dd,J=4.7,1.5Hz,2H),8.25(dd,J=8.7,2.4Hz,1H),7. 74(d,J=8.7Hz,1H),7.15(dd,J=4.7,1.5Hz,2H),1.97(t,J=8.1Hz,4H),1.67(t,J=7.4Hz,4H),1.40(s,9H).

[0351] Example 96: Synthesis of Labelled Precursor 96

[0352]

[0353] According to the synthesis method of Example 95, compound 59 was used as the raw material to synthesize the labeled precursor 96 to obtain 35.9 mg of a yellow oily product with a yield of 46.2%. 1 H NMR (600MHz, CDCl3) δ8.70(d,J=2.3Hz,1H),8.51(d,J=5.5Hz,1H),8.26(dd,J=9.0,2.4Hz,1H),7.85(d,J=8.9Hz, 1H),6.96(s,1H),6.90(dd,J=5.4,1.7Hz,1H),2.59(s,3H),2.15(t,J=7.5Hz,4H),1.82–1.78(m,4H),1.45(s,9H).

[0354] Example 97: Synthesis of Compound 97

[0355]

[0356] According to the synthesis method of Example 63, compound 97 was synthesized using 4-methoxypyridine and 2-fluoroaniline as raw materials to obtain 83.3 mg of a white solid product with a yield of 41%. 1 H NMR (400MHz, CDCl3) δ8.29 (d, J = 5.7Hz, 2H), 7.42 (t, J = 7.1Hz, 1H), 7.14 (td, J = 14.2, 12.3, 6.9Hz, 3H), 6.87 (d, J = 5.8Hz, 2H). HRMS: m / z = 189.08208 [C 11 H 10 N2F] + .

[0357] Example 98: Synthesis of Compound 98

[0358]

[0359] According to the synthesis method of Example 63, compound 98 was synthesized using 4-methoxypyridine and 3-fluoroaniline as raw materials to obtain 55.2 mg of a white solid product with a yield of 35%. 1 H NMR(600MHz, (CD3)2SO) δ30.73(d,J=6.2Hz,2H),29.85(q,J=8.0Hz,1H),29.52(d,J=8 .1Hz,1H),29.50–29.44(m,3H),29.31(td,J=8.4,2.1Hz,1H).HRMS:m / z=189.08221[C 11 H 10 N2F] + .

[0360] Example 99: Synthesis of Compound 99

[0361]

[0362] According to the synthesis method of Example 63, 4-methoxypyridine and 4-fluoroaniline were used as raw materials to synthesize compound 99 to obtain 71.1 mg of a white solid product with a yield of 38%. 1H NMR (600 MHz, (CD3)2SO) δ 8.20 (d, J = 5.7 Hz, 2H), 7.32–7.21 (m, 4H), 6.91 (d, J = 5.6 Hz, 2H). HRMS: m / z = 189.08223 [C 11 H 10 N2F] + .

[0363] Example 100: Synthesis of Compound 100

[0364]

[0365] According to the synthesis method of Example 63, compound 100 was synthesized using 4-methoxy-2-methylpyridine and 2-fluoroaniline as raw materials to obtain 52.5 mg of a white solid product with a yield of 56%. 1 H NMR (600MHz, CDCl3) δ8.20(d,J=5.6Hz,1H),7.41(t,J=7.9Hz,1H),7.15(q,J=8.2,7.2 Hz,2H),7.08(q,J=6.8Hz,1H),6.74–6.68(m,2H),2.46(s,3H).HRMS:m / z=203.09799[C 12 H 12 N2F] + .

[0366] Example 101: Synthesis of Compound 101

[0367]

[0368] According to the synthesis method of Example 63, compound 101 was synthesized using 4-methoxy-2-methylpyridine and 3-fluoroaniline as raw materials to obtain 36.6 mg of a white solid product with a yield of 52.2%. 1 H NMR (600MHz, CDCl3) δ8.18(d,J=5.5Hz,1H),7.32–7.27(m,1H),6.94(d,J=8.0Hz,1H),6.91(dt,J=1 0.3, 2.2Hz, 1H), 6.80 (t, J = 8.3Hz, 1H), 6.75 (d, J = 5.0Hz, 2H), 2.47 (s, 3H). HRMS: m / z = 203.09796 [C 12 H 12 N2F] + .

[0369] Example 102: Synthesis of Compound 102

[0370]

[0371] According to the synthesis method of Example 63, compound 102 was synthesized using 4-methoxy-2-methylpyridine and 4-fluoroaniline as raw materials to obtain 32.9 mg of a white solid product with a yield of 28.7%. 1 H NMR (600MHz, CDCl3) δ8.14(d,J=5.6Hz,1H),7.19–7.13(m,2H),7.07(t,J=8.5Hz,2H),6.61–6.54(m,2H),2.44(s,3H).HRMS:m / z=203.09798[C 12 H 12 N2F] + .

[0372] Example 103: Synthesis of Compound 103

[0373]

[0374] According to the synthesis method of Example 1, compound 103 was synthesized using 2-aminothiazole and 2,5-iodopyridine as raw materials to obtain 11.3 mg of white powder with a yield of 49.2%. 1H NMR(600MHz, (CD3)2SO) δ8.48(d,J=2.0Hz,1H),7.97(dd,J=8.7,2.2Hz,1H),7.39(d,J=3 .6Hz,1H),7.04(d,J=3.6Hz,1H),6.97(d,J=8.7Hz,1H).HRMS:m / z=303.93994[C8H7N3IS] + .

[0375] Example 104: Synthesis of Labeled Precursor 104

[0376]

[0377] According to the synthesis method of Example 4, compound 103 was used as a raw material to synthesize the labeled precursor 104 to obtain 35.9 mg of a yellow oily product with a yield of 46.2%. 1 H NMR (400MHz, CDCl3) δ8.35(s,1H),7.66(dd,J=8.0,1.5Hz,1H),7.49(d,J=3.1Hz,1H),6.94(d,J=8.0Hz,1H),6.85(d ,J=3.7Hz,1H),1.57–1.49(m,4H),1.37–1.29(m,6H),1.13–1.04(m,5H),0.96–0.86(m,12H).HRMS:m / z=468.14908[C 20 H 34 N3SSn] + .

[0378] Example 105: Synthesis of Compound 105

[0379]

[0380] According to the synthesis method of Example 7, compound 105 was synthesized using 4-aminoquinoline and 2-bromo-5-iodopyridine as raw materials to obtain 211.1 mg of a light yellow solid with a yield of 56.3%. 1 H NMR(400MHz, (CD3)2SO) δ9.52(s,1H),8.67(d,J=5.2Hz,1H),8.51(d,J=2.3Hz,1H),8.45(d,J=8.0Hz,1H),8.28(d,J=5.2Hz,1H),8.04(d d,J=8.7,2.4Hz,1H),7.94(d,J=8.3Hz,1H),7.73(t,J=7.6Hz,1H),7.59(t,J=7.6Hz,1H),7.24(d,J=8.7Hz,1H).HRMS: m / z=347.99893[C14 H 11 N3I] + .

[0381] Example 106: Synthesis of Compound 106

[0382]

[0383] According to the synthesis method of Example 7, compound 106 was synthesized using 4-aminoquinaldine and 2-bromo-5-iodopyridine as raw materials to obtain 78.2 mg of a light yellow solid with a yield of 37.3%. 1 H NMR(600MHz, (CD3)2SO) δ9.43(s,1H),8.48(s,1H),8.34(d,J=8.5Hz,1H),8.12(s,1H),8.00(dd,J=8.7,2.2Hz,1H),7.81( d,J=8.4Hz,1H),7.65(t,J=7.6Hz,1H),7.48(t,J=7.6Hz,1H),7.19(d,J=8.7Hz,1H),2.53(s,3H).HRMS:m / z=362.01487[C 15 H 13 N3I] + .

[0384] Example 107: Synthesis of Labeled Precursor 107

[0385]

[0386] According to the synthesis method of Example 4, compound 105 was used as a raw material to synthesize the labeled precursor 107 to obtain 33.0 mg of a yellow oily product with a yield of 28.1%. 1 H NMR (600MHz, CDCl3) δ8.55(s,1H),8.39(s,1H),8.17(d,J=7.4Hz,1H),8.14(d,J=8.2Hz,1H),8.07(s,1H),7.80(d,J=8.0Hz,1H),7.69(t,J=8. 1Hz,1H),7.57(t,J=7.7Hz,1H),7.40(s,1H),1.64–1.54(m,4H),1.41–1 .32(m,6H),1.14–1.10(m,5H),0.95–0.87(m,12H).MS:m / z=512.3674[C 26 H 38 N3Sn] + .

[0387] Example 108: Synthesis of Labeled Precursor 108

[0388]

[0389] According to the synthesis method of Example 4, compound 106 was used as a raw material to synthesize the labeled precursor 108 to obtain 31.9 mg of a yellow oily product with a yield of 16.9%. 1 H NMR (400MHz, CDCl3) δ8.35(s,1H),8.01(d,J=8.4Hz,1H),7.92(d,J=8.3Hz,1H),7.77–7.63(m,3H),7.52–7.45(m,1H),7.15(d ,J=8.0Hz,1H),2.70(s,3H),1.67–1.52(m,4H),1.43–1.25(m,6H),1.14–1.08(m,5H),0.95–0.85(m,12H).MS:m / z=526.3942[C 27 H 40 N3Sn] + .

[0390] Example 109: Synthesis of Compound 109

[0391]

[0392] According to the synthesis method of Example 7, compound 109 was synthesized using 4-aminopyridine and 5-bromo-2-(4-iodophenyl)pyridine as raw materials to obtain 56.8 mg of a light yellow solid with a yield of 69.2%. 1 H NMR(600MHz, (CD3)2SO) δ8.67(d,J=2.5Hz,1H),8.42(d,J=6.5Hz,2H),8.09(dd,J=8.6,2.5Hz,1H),7.92(d ,J=5.4Hz,2H),7.84(d,J=8.3Hz,2H),7.53(d,J=8.3Hz,2H),7.14(d,J=8.6Hz,1H).HRMS:m / z=374.01480[C 16 H 13 N3I] + .

[0393] Example 110: Synthesis of Labeled Precursor 110

[0394]

[0395] According to the synthesis method of Example 4, compound 109 was used as a raw material to synthesize the labeled precursor 110 to obtain 8.1 mg of a yellow oily product with a yield of 12.6%. 1H NMR (600MHz, CDCl3) δ8.57(s,1H),8.37(d,J=5.3Hz,2H),7.85(d,J=8.5Hz,1H),7.59–7.55(m,4H),7.52(d,J=6.6Hz,2H) ,7.11(d,J=8.5Hz,1H),1.61–1.52(m,4H),1.41–1.30(m,6H),1.14–1.10(m,5H),0.93–0.87(m,12H).MS:m / z=358.2212[C 28 H 40 N3Sn] + .

[0396] Example 111: Synthesis of Compound 111

[0397]

[0398] According to the synthesis method of Example 7, compound 111 was synthesized using 4-aminopyridine and 2-chloro-6-iodobenzothiazole as raw materials to obtain 29.4 mg of a gray solid with a yield of 22.2%. 1 H NMR(400MHz, (CD3)2SO) δ10.99(s,1H),8.45(d,J=6.2Hz,2H),8.27(d,J=1.6Hz,1H),7.73(d d,J=4.9,1.3Hz,2H),7.67(dd,J=8.4,1.7Hz,1H),7.50(d,J=8.4Hz,1H).MS:m / z=305.9611[C 12 H9BrN3S] + .

[0399] Example 112: Synthesis of Compound 112

[0400]

[0401] According to the synthesis method of Example 7, compound 112 was synthesized using 4-aminopyridine and 2-chloro-6-fluorobenzothiazole as raw materials to obtain 27.1 mg of a white solid with a yield of 60.3%. 1 H NMR(600MHz, (CD3)2SO) δ10.95(s,1H),8.42(d,J=5.2Hz,2H),7.78(d,J=8.7Hz,1H),7.72 (d,J=5.0Hz,2H),7.70(dd,J=8.9,4.9Hz,1H),7.26–7.18(m,1H).HRMS:m / z=246.04968[C 12 H9N3FS] + .

[0402] Example 113: Synthesis of Compound 113

[0403]

[0404] According to the synthesis method of Example 7, compound 113 was synthesized using 4-aminopyridine and 2-chloro-6-fluorobenzoxazole as raw materials to obtain 102.2 mg of a white solid with a yield of 71.5%. 1 H NMR(400MHz, (CD3)2SO) δ11.19(s,1H),8.46(d,J=5.5Hz,2H),7.70(d,J=6.2Hz,2H),7.59(d d,J=8.4,2.2Hz,1H),7.53(dd,J=8.6,4.9Hz,1H),7.17–7.09(m,1H).HRMS:m / z=230.07210[C 12 H9ON3F] + .

[0405] Example 114: Synthesis of Compound 114

[0406]

[0407] According to the synthesis method of Example 4, compound 111 was used as a raw material to synthesize the labeled precursor 114 to obtain 41.2 mg of a white solid product with a yield of 32.8%. 1 H NMR (400MHz, CDCl3) δ8.44(d,J=6.3Hz,1H),7.78–7.71(m,2H),7.71–7.63(m,2H),7.55(d,J=7.5Hz,1H),7.47(d ,J=7.6Hz,1H),1.61–1.52(m,4H),1.41–1.30(m,6H),1.14–1.10(m,5H),0.93–0.87(m,12H).MS:m / z=518.1899[C 24 H 36 N3SSn] + .

[0408] Example 115: Synthesis of Compound 115

[0409]

[0410] Precursor 114 (65 mg, 0.13 mmol) was dissolved in dichloromethane, and a dichloromethane solution containing I2 was added dropwise thereto. The mixture was reacted at room temperature for 1 hour, and sodium thiosulfate was added and stirred until the solution became colorless. The solid was removed by suction filtration, and the solvent was removed by vacuum distillation. 38.6 mg of a white solid was obtained by column chromatography with a yield of 92.9%.1 H NMR(400MHz, (CD3)2SO) δ8.45(d,J=6.2Hz,2H),8.27(d,J=1.6Hz,1H),7.73(d,J=6. 2Hz, 2H), 7.67 (dd, J=8.4, 1.7Hz, 1H), 7.50 (d, J=8.4Hz, 1H). HRMS: m / z=353.95575[C 12 H9N3IS] + .

[0411] Embodiment 116: 125 I and 18 Preparation of F-labeled compounds

[0412] (a) Compound [ 125 I]1-3, [ 125 I]7,[ 125 I]9,[ 125 I]10,[ 125 I]16-18, 125 I]22-26, 125 I]32-34, [ 125 I]36,[ 125 I]38,[ 125 I]45,[ 125 I]46,[ 125 I]48,[ 125 I]50-52, 125 I]56,[ 125 I]58,[ 125 I]69,[ 125 I]71-74, 125 I]103,[ 125 I]105-106, 125 I]109 and [ 125 Preparation of I]115

[0413] 0.1 mg of labeled precursor (compounds 4-6, 8, 11, 12, 19-21, 27-31, 39-44, 47, 49, 53-55, 57, 60, 70, 76-79, 104, 107-108, 110, 114) was dissolved in 100 μL of ethanol and 100 μCi of Na 125 I solution, 50 μL hydrochloric acid (1M) and 100 μL 3% hydrogen peroxide solution, react at room temperature for 15 minutes, add NaHCO3 until the pH is neutral, then purify by HPLC, collect the target product effluent, remove acetonitrile with nitrogen, and prepare the obtained product into the required solution.

[0414] (b) Compound [125 I]59,[ 125 I]63 and [ 125 Preparation of I]64

[0415] 0.1 mg of labeled precursor (compounds 62, 67 and 68, respectively) was dissolved in 100 μL of ethanol and 100 μCi of Na 125 I solution, 100 μL hydrochloric acid (1M) and 100 μL 3% hydrogen peroxide solution, react at room temperature for 15 minutes, then heat at 100°C for 3 minutes, and add NaHCO3 after cooling until the pH is neutral. Then HPLC purification is performed, the target product effluent is collected, acetonitrile is removed by nitrogen, and the obtained product is prepared into the desired solution.

[0416] (c) Compound [18F]13, [ 18 F]81,[ 18 F]85 and [ 18 Preparation of F]88

[0417] The enriched samples on the QMA column were washed with 1 mL of eluent (containing Kryptofix-2.2.2 18.0 mg, K2CO3 1.1 mg, acetonitrile / water = 4 / 1). 18 F]F - The ions were eluted into a glass reaction tube, heated in a metal bath at 120°C, and N2 was continuously introduced to dry the system to ensure that the system was anhydrous. 2.5 mg of the labeled precursor (Compound 15, Compound 94-96) was dissolved in 300 μL of anhydrous DMF and transferred to the reaction tube. The reaction was carried out at 120°C for 10 minutes, and after cooling, 100 μL of 1M HCl solution was added. The reaction was carried out at 100°C for 5 minutes, and after cooling, 100 μL of 1M NaOH solution was added. The mixture was separated and purified by HPLC, and the separation conditions were: Venusil MP C18 reverse column (5 μm, 10 mm × 250 mm), the effluent of the target product was collected, the solvent was dried with nitrogen, and the product was dissolved in 10% ethanol and diluted with purified water for use.

[0418] (d) Preparation of Compound [18F]80

[0419] [ 18 F]F - The ions were enriched on the QMA column and 1 mL of eluent (containing 6.8 mg of TBAB, acetonitrile / water = 7 / 3) was used to 18 F]F - Elute from the QMA column. Take about 20mCi of fluoride ion solution and add it to a 10mL glass reaction tube, heat it in a 120℃ metal bath, and continuously blow N2 to dry it to ensure that the reaction system is dry. Dissolve 1mg of the labeled precursor compound (Compound 91) in 300μL of anhydrous DMSO and transfer the solution to a 10mL glass reaction tube containing [18 F]F - The reaction was heated at 100°C for 8 minutes. After cooling, the product was separated and purified by HPLC under the following separation conditions: Venusil MP C18 reverse column (5 μm, 10 mm × 250 mm). The effluent of the target product was collected, the solvent was dried with nitrogen, and the obtained product was dissolved in 10% ethanol and prepared with purified water to the required concentration.

[0420] 2. Experimental Results

[0421] [ 125 I]1-3, [ 125 I]7,[ 125 I]9,[ 125 I]10,[ 18 F]13,[ 125 I]16-18, 125 I]22-26, 125 I]32,[ 125 I]33,[ 125 I]34,[ 125 I]36,[ 125 I]38,[ 125 I]45,[ 125 I]46,[ 125 I]48,[ 125 I]50-52, 125 I]56,[ 125 I]58,[ 125 I]69,[ 125 I]71-74, 18 F]80,[ 18 F]85,[ 18 F]88,[ 125 I]103,[ 125 I]105-106, 125 I]109 and [ 125 The labeling rate of I]115 is as follows. After HPLC purification, the radiochemical purity is greater than 95%. The chromatographic column is a VenusilMP C18 reverse column (5μm, 10mm×250mm or 4.6mm×250mm), the mobile phase flow rate is 4mL / min or 1mL / min, and the radiochemical conversion rate is shown in Table 1.

[0422] Table 1: Radiochemical conversion of labeled compounds

[0423]

[0424]

[0425] Example 117: Autoradiography Experiment

[0426] A certain concentration of labeled product (10% ethanol solution) was incubated with AD patient brain slices at room temperature for a certain period of time. After the incubation, the slices were exposed through a phosphor screen and then exposed using a storage phosphor screen system ( Plus (Perkin-Elmer, USA) scanned and analyzed the images.

[0427] 1. Experimental steps:

[0428] (1) Pretreatment of AD human brain paraffin sections;

[0429] (2) Cover AD human brain slices with 5 μCi / mL of 125 I-labeled or 20 μCi / mL 18 1 mL of F-labeled compound solution was incubated at room temperature for 1-2 hours;

[0430] (3) Rinse with 40% ethanol solution for 3 minutes, followed by 20% ethanol for 5 minutes;

[0431] (4) After drying, wrap with plastic wrap and expose under a phosphor screen for 24 hours ( 125 I labeled compound) or 1 hour ( 18 F labeled compound), using a storage phosphor screen system Plus (Perkin-Elmer, USA) scanned and analyzed the images.

[0432] 2. Experimental results:

[0433] The experimental results are as follows Figure 13-15 As shown, it is fully demonstrated that compound 10, compound 13, compound 58, compound 59, compound 64, compound 88, compound 105, compound 109 and compound 116 of the present invention have high Tau activity and high Aβ selectivity after being labeled with radioactive nuclides, can be used as Tau protein imaging agents in AD brain, and have potential application prospects in clinical diagnosis of AD.

[0434] Example 118: Biodistribution experiment in normal mice

[0435] 1. Experimental steps:

[0436] 5-10 μCi 18 F-labeled compound or 1-2 μCi 125I-labeled compounds (100 μL physiological saline solution containing 10% ethanol) were injected into normal mice (ICR, male, 18-20 g, 3-4 weeks old) via the tail vein (n=3 or 5). The relevant organs were removed by dissection at 2 minutes, 10 minutes, 30 minutes and 60 minutes after injection, and the wet weight and radioactivity counts were measured. The data are expressed as the percentage of radioactivity per gram of organ (%ID / g).

[0437] 2. Experimental results:

[0438] The experimental results are shown in Table 2. The probes described in the present invention [ 125 I]10,[ 18 F]13, [ 125 I]58,[ 125 I]59,[ 18 F]85 and [ 18 F]88 can pass through the blood-brain barrier smoothly, with brain uptake reaching a peak at 2 minutes and clearing quickly in the brain of normal mice. It meets the basic requirements of central nervous system PET imaging agents and has the potential to be developed into Tau protein PET imaging agents.

[0439] Table 2: Animal distribution results of some compounds in normal mice

[0440]

[0441]

[0442]

[0443] Example 119: IC of Compounds and Human Brain Tau Protein 50 Value determination

[0444] 1. Experimental steps:

[0445] (1) Pretreatment of AD human brain paraffin sections;

[0446] (2) Cover AD human brain slices with 10 μCi / mL 125 1 mL of the compound solution labeled with I was added with a stable cold ligand (final concentrations of 0.01, 0.1, 0.5, 1, 5, 10 and 100 nM or 0.01, 0.1, 1, 5, 10, 100 and 1000 nM) and incubated at room temperature for 2 hours;

[0447] (3) Rinse with pure ethanol or 50% ethanol solution for 3 minutes, followed by rinsing with 20% ethanol solution for 5 minutes;

[0448] (4) After drying, wrap with plastic wrap and expose under a phosphor screen for 24 hours. Plus (Perkin-Elmer, USA) scans and analyzes images to obtain the quantitative values ​​of Region of interests (ROIs) (Digital Light Unit / mm 2 , DLU / mm 2 ), and the half inhibition constant (IC 50 ) is obtained through fitting calculation.

[0449] 2. Experimental results:

[0450] The experimental results are as follows Fig.15 As shown, the IC of compound 10 50 The value was 5.54 nM, and the IC of compound 13 50 The value was 22.16 nM, and the IC of compound 59 50 The value was 10.25 nM, and the IC of compound 63 50 The value was 9.32 nM, and the IC of compound 64 50 The value was 18.09 nM, and the IC of compound 88 50 The value was 7.20 nM, and the IC of compound 98 50 The value was 9.03 nM, and the IC of compound 101 50 The value is 6.01nM, such as Fig.16 As shown, it is shown that compounds 10, 13, 59, 63, 64, 88, 98 and 101 of the present invention have high affinity for Tau protein.

[0451] Example 120: Tau K d Value determination

[0452] 1. Experimental steps:

[0453] (1) Pretreatment of AD human brain paraffin sections;

[0454] (2) AD human brain slices were coated with 1, 5, 10, 50, 100 and 500 μCi / mL of [ 18 F]13 or 1, 5, 10, 50, 100, 500, 1000, 2000 μCi / mL [ 18 F]88 in 10% ethanol solution, incubate at room temperature for 1 hour;

[0455] (3) Rinse with 40% ethanol solution for 1 minute, followed by 50% ethanol solution for 3 minutes;

[0456] (4) After drying, wrap with plastic wrap and expose under a phosphor screen for 1 hour. Plus (Perkin-Elmer, USA) scans and analyzes images to obtain the quantitative values ​​of Region of interests (ROIs) (Digital Light Unit / mm 2 , DLU / mm 2 ), according to the numerical value and the corresponding concentration fitting curve, the dissociation constant (K d ) is obtained through fitting calculation.

[0457] 2. Experimental results:

[0458] The experimental results are as follows Fig.16 As shown, the K of compound 13 d The value was 23.95 nM, and the K d The value is 10.92 nM, indicating that compound 13 and compound 88 of the present invention have high activity against Tau protein.

[0459] Example 121: Aβ Activity Assay

[0460] 1. Experimental steps

[0461] (1) 100 μL of radioligand ([ 125 I] IMPY, 1 μCi / mL), 100 μL of ethanol solution of compounds 1-3, 7, 9-10, 13, 16-18, 22-26, 32-34, 36, 38, 45-46, 48, 50-52, 56, 58, 59, 63-64, 69, 71-75, 80-89, 97-103, 105-106, 109, 112-113, 115 (10 -4 M to 10 -10 M), 700 μL BSA (0.1% PBS solution) and Aβ 1-42 Aggregates (100 μL, final concentration 0.7 μM) were added sequentially into borosilicate glass test tubes.

[0462] (2) Incubate at 37°C for 2 hours.

[0463] (3) The cells were separated by filtration using an MP-48T cell collector and washed three times with 10% ethanol.

[0464] (4) Collect the samples containing Aβ 1-42 Aggregate-bound 125 The glass fiber filter paper containing the I ligand was placed at the bottom of the numbered counting tubes, and the radioactive counts in each counting tube were measured. The half inhibition constant (IC 50 ) is obtained through fitting calculation.

[0465] 2. Experimental Results

[0466] The experimental results are shown in Table 3. Compounds 1-3, 7, 9-10, 13, 16-18, 22-26, 32-34, 36, 38, 45-46, 48, 50-52, 56, 58, 59, 63-64, 69, 71-75, 80-89, 97-103, 105-106, 109, 112-113, 115 had no significant effect on Aβ activity (IC 50 ) were all greater than 500 nM, indicating that they had poor binding ability to Aβ. Compounds 33, 45, 81 and 109 had poor Aβ activity (IC 50 ) were better, 46.0nM, 42.0nM, 76.8nM, 45.3nM, and 42.9nM respectively. The above results were obtained Fig.13 Verification of in vitro autoradiography results.

[0467] Table 3: Some Compounds Aβ 1-42 Activity test results

[0468]

[0469]

[0470] Example 122: PET / CT Imaging in Rodents and Rhesus Monkeys

[0471] 1. Experimental steps

[0472] (a) Rodent PET / CT imaging

[0473] Will[ 18 F]13 injection (2.793-9.735 MBq, 10% ethanol solution) or [ 18 F]88 injection (5.269-5.879MBq, 10% ethanol solution) was injected into normal ICR mice or SD rats (3 males in each group) through the tail vein, and PET dynamic scanning for 0-60min was immediately started. During the acquisition process, continuous inhalation of a mixture of isoflurane and air was used for anesthesia, and the gas flow rate was 1.2L / min. After the PET data acquisition was completed, CT acquisition was completed to obtain anatomical information. The PET data was reconstructed in 3D-OSEM mode, and the dynamic data of ICR mice was framed in 20×60s and 8×300s, and the dynamic data of SD rats was framed in 20×30s, 4×300s and 3×600s. The reconstructed data was imported into PMOD 4.1 software to complete the quantitative analysis of the data and export of PET images.

[0474] (b) PET / CT imaging of rhesus monkeys

[0475] A rhesus monkey (female, 38 years old, 4.9 kg) was anesthetized in advance by intramuscular injection of ketamine, and a drug delivery channel was established in its hind limb vein. The rhesus monkey was placed on the scanning bed in a lateral position, and CT scanning was started to collect anatomical structure data and positioning information. After determining the scanning range from the top of the skull to the base of the skull, the [ 18 F]13 (21.61MBq / kg) was injected intravenously into rhesus monkeys, and dynamic scanning was performed at 0-30min, static brain scanning was performed at 30-40min, 40-50min, and 50-60min, and static whole-body scanning was performed at 60-70min. The reconstructed data were imported into PMOD 4.1 software to complete data quantitative analysis and PET image export.

[0476] 2. Experimental Results

[0477] like Figure 17-19 As shown, 18 F]13 can rapidly cross the blood-brain barrier of rodents and rhesus monkeys and reach the peak of brain uptake within 3 min (SUV max =2.49, SD rat SUV max =2.46, Rhesus SUV max =1.84), was rapidly cleared from the brains of healthy rodents and rhesus monkeys, and had no off-target binding in key brain regions such as the basal ganglia.

[0478] like Fig. 20 As shown, 18 F]88 can quickly cross the blood-brain barrier of rodents, reaching a peak brain uptake at 5 minutes, and the kinetic curve of the whole brain is consistent, with no non-target signal retention. 18 F]13 and [ 18 F]88 meets the basic requirements of central nervous system imaging agents and is expected to be developed into a clinically valuable PET imaging agent targeting Tau protein in the brains of AD patients.

[0479] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A diarylamine compound, It is characterized in that The diarylamine compound has the following general formula (I): Among them, Ar 1 Preferably means Ar 2 express R stands for 123 / 125 / 127 I, 18 / 19 F, O 11 / 12 CH 3 , (OCH 2 CH 2 ) m R 1 , Where R 1 for 18 / 19 F, m is an integer between 1-6.

2. The diarylamine compound according to claim 1, It is characterized in that Selected from the following compounds: Among them, I and F can both refer to their isotopes at the same time, such as: 123 / 125 / 127 I and 18 / 19 F; Among them, in compounds 1-6, compounds 8-37, and compounds 54-58, I is 123 I, 125 I or 127 I; In compound 7, compounds 38-53, and compounds 59-60, F is 18 F or 19 F.

3. The derivative of the diarylamine compound according to claim 1 or 2, It is characterized in that These include pharmaceutically acceptable salts, esters or amides.

4. A diagnostic or detection reagent for a neurofibrillary tangle disease caused by Tau protein deposition, It is characterized in that The active ingredient is the diarylamine compound described in claim 1 or 2, and / or the derivative described in claim 3.

5. The diagnostic or detection reagent according to claim 4, It is characterized in that Such diseases include Alzheimer's disease, frontotemporal lobar degeneration, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration or Pick's disease.

6. Use of the diarylamine compound according to claim 1 or 2, or the derivative according to claim 3, in the preparation of a nuclear medicine imaging agent.

Citation Information

Patent Citations

  • 2-arylquinoxaline compound having affinity to Tau protein and preparation method and use thereof

    CN108047145A